|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
01/2011 | Recent | 13: May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositions January recently filed with US Patent Office 01/11Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 01/27/2011 > 266 patent applications in 117 patent subcategories. recently filed with US Patent Office
20110020216 - Scaffolds for cell collection or elimination: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20110020217 - Treatment of melanoma: There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto.... Agent: K&l Gates LLP
20110020219 - Anti-human tenascin monoclonal antibody: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both... Agent: Nixon & Vanderhye, PC
20110020221 - Cancer stem cell expression patterns and compounds to target cancer stem cells: Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer... Agent: Edwards Angell Palmer & Dodge LLP
20110020220 - Humanized antibodies against the beta-amyloid peptide: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective... Agent: Marshall, Gerstein & Borun LLP
20110020222 - Modified antibodies and methods of use: Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly... Agent: Nelson Mullins Riley & Scarborough / Biogen Floor 30, Suite 3000
20110020224 - Apparatus and method for preparing medicines containing radioactive substances: An apparatus (1) for preparing medicines containing radioactive substances, more specifically injectable medicines containing beta-emitting substances, in which a radioactive element is combined, in a mixture, with a protein to be labelled using the radioactive element; the mixture is then subjected to a chromatographic separation step which separates the mixture... Agent: Pearne & Gordon LLP
20110020223 - Polypeptides having affinity for her2: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides... Agent: Wiggin And Dana LLP Attention: Patent Docketing
20110020230 - Biomarkers for prostate cancer: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the prostate. In particular, the present invention provides compositions and methods for using neuroligin biomarkers (e.g., NLGN-4Y) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy).... Agent: Casimir Jones, S.c.
20110020229 - Multi-component biological transport systems: Compositions and methods are provided that are useful for the delivery of therapeutic agents, including nucleic acids. The compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.... Agent: King & Spalding
20110020226 - Particle structures comprising sterols and saponins: The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20110020227 - Polysaccharide-containing block copolmer particles and uses thereof: The invention relates to new amphiphilic linear block copolymers of polysaccharides and polymers. The amphiphilic linear block copolymers do not form a true solution in water and are able to form micelles in selective solvents. Also disclosed are particles, each of which has a shell and a core, and a... Agent: Mccarter & English, LLP Boston
20110020225 - Porous polymer particles immobilized with charged molecules and method for preparing the same: The present invention relates to porous polymer particles containing a charged molecule immobilized therein and a method for preparing the same. According to the disclosed invention, porous particles can be prepared using a biocompatible polymer and, at the same time, a charged molecule can be immobilized in the pores of... Agent: Moore & Van Allen PLLC
20110020231 - Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a-e and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for... Agent: Theravance, Inc.
20110020228 - Targeted cellular selectivity of surface active molecules: A method for the treatment of cancer involves delivering a surface active agent to an organism, where the surface active agent selectively partitions to and kills cancer cells as opposed to healthy cells. The surface active agent can be an ionic or a non-ionic surfactant with a HLB of less... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20110020232 - Cancer treatment with gama-secretase inhibitors: m
20110020233 - Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective... Agent: Mckee, Voorhees & Sease, P.L.C
20110020234 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20110020236 - Method for the synthesis of hollow spheres: The present invention relates to a method of synthesizing acoustically active biodegradable hollow spheres with a size below 1 micron. By using water soluble organic solvents and pegylated polymers, direct precipitation of these spheres is facilitated leading to a fast and convenient preparation route.... Agent: Philips Intellectual Property & Standards
20110020235 - Mr methods of grading a tumor using an imaging medium that comprises hyperpolarised 13c-pyruvate: The invention relates to MR methods of grading a tumor using an imaging medium which comprises hyperpolarized 13C-pyruvate.... Agent: Ge Healthcare, Inc.
20110020242 - High-density lipoprotein-like peptide-phospholipid scaffold (\"hpps\") nanoparticles: The present invention provides a non-naturally occurring High-Density Lipoprotein-like peptide-phospholipid scaffold (“HPPS”) nanoparticle. More particularly, the invention provides a non-naturally occurring peptide-lipid nanoscaffold comprising: (a) at least one phospholipid; (b) at least one unsaturated lipid, preferably an unsaturated sterol ester, further preferably an unsaturated cholesterol ester, further preferably cholsteryl oleate;... Agent: Pepper Hamilton LLP
20110020237 - Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders: Compositions of matter and methods for inhibiting drusen or drusen-like deposits and/or for treating diseases related to drusen or drusen-like deposits in human or animal subjects by administering to the subject a therapeutically effective amount of i) a conformational epitope of an aggregate that contributes to the formation or biosynthesis... Agent: Stout, Uxa, Buyan & Mullins LLP
20110020238 - Stabilizing aqueous solution of iodine chloride by adding sodium chloride: This invention relates generally to non-ionic X-ray contrast agents. It further relates to the preparation of iodine chloride, a key reagent in the synthesis of non-ionic X-ray contrast agents such as iodixanol and iohexol. In particular, the iodine chloride is produced in a reaction involving iodine, sodium chlorate, and hydrochloric... Agent: Ge Healthcare, Inc.
20110020243 - Methods and compositions for imaging cancer cells: Disclosed are compositions comprising nanoparticles and uses thereof. Such nanoparticles include gold nanoparticles conjugated to glucose or a glucose derivative, which are useful as contrast agents in imaging methods such as computed tomography (CT). Nanoparticles disclosed herein are useful in imaging various cells, tissues, and organs, and are particularly useful... Agent: Fulbright & Jaworski L.L.P.
20110020241 - Fluorescent labeling agent containing quantum dots: Disclosed is a fluorescent labeling agent containing quantum dots, which exhibits little fluctuation in luminous properties in accordance with the environment where the fluorescent labeling agent is stored and therefore has high environmental stability, and which has high luminous intensity. Specifically disclosed is a fluorescent labeling agent containing quantum dots,... Agent: Lucas & Mercanti, LLP
20110020239 - Methods for in vivo imaging of cells: The instant invention provides methods for the in vivo imaging of cells using one or more imaging modalities.... Agent: Edwards Angell Palmer & Dodge LLP
20110020240 - Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics: Provided herein are imaging methods for detecting, diagnosing and imaging pathogenic bacteria or a pathophysiological condition associated therewith using fluorogenic substrates for bacterial enzymes. Fluorescent, luminescent or colorimetric signals emitted by substrates or enzyme products in the presence of the bacteria are compared to controls to detect and locate the... Agent: Benjamin Aaron Adler Adler & Associates
20110020244 - Pharmaceutical compositions: The present invention relates to pharmaceutical compositions and in particular to suspension aerosol pharmaceutical compositions, processes to obtain them and their use in inhalation therapy.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket
20110020245 - Functionalized calcium phosphate hybrid systems for confectionery and foodstuff applications: A method for repairing dentition, including milling beta tricalcium phosphate with sufficiently high energy to substantially distressed its lattice structure, mechanochemically chelating an edible acid thereto to yield functionalized calcium phosphate moieties, and incorporating the functionalized calcium phosphate moieties into an edible material to yield a calcium phosphate delivery system.... Agent: Brannon & Sowers PC
20110020246 - Oral care compositions which comprise stannous and potassium: m
20110020248 - Oral care compositions which comprise stannous and potassium:
20110020247 - Oral care compositions which comprise stannous, potassium and monofluorophophates: The composition of the invention has been found to allow prolonged contact between stannous ion and nitrate ion in a single dentifrice without toxic effects or insoluble products. The invention further provides for the maintenance of an efficacious fluoride ion level.... Agent: The Procter & Gamble Company Global Legal Department - Ip
20110020249 - Polyorganosiloxane with a piperidine function, devoid of toxicity upon contact with the skin, and use thereof in cosmetic compositions: The invention relates to polyorganosiloxanes containing, per molecule, at least one siloxyl unit substituted with at least one group having one or more sterically hindered piperidinyl functional groups, devoid of toxicity upon contact with the skin. The invention also relates to an improved cosmetic composition comprising the polyorganosiloxanes according to... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC
20110020252 - Method of long lasting human skin tanning: The invention relates to the use of Rifampin and its related compound as a method of producing long-lasting, effective skin tanning for human and animal. The invention relates to methods of accelerating and facilitating the tanning of the skin using Rifampin along with use of the other tanning facilitators and... Agent: Patwrite LLC
20110020250 - Personal-care composition comprising a hydrocarbon wax and a polar oil: In one embodiment, a stable personal-care composition in the form of a water-in-oil emulsion may comprise a hydrocarbon wax, a polar oil, and a non-emulsifying silicone elastomer. In another embodiment, a stable personal-care composition in the form of a water-in-oil emulsion may comprise a hydrocarbon wax and a polar oil.... Agent: The Procter & Gamble Company Global Legal Department - Ip
20110020251 - Ultraviolet-absorbing compounds:
20110020253 - Body wash with sunscreen system and method: A body wash composition includes sunscreen or UV screen materials. The body wash composition is formulated so that it may be applied during normal hygiene activities, such as washing. However, the composition applies an effective level of sunscreen or UV screen material to the body such that the sunscreen or... Agent: Duke W. Yee
20110020254 - Refreshing cream foundation in gel form: The present invention is directed to a cosmetic composition includes (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) at least one gelling agent; (d) at least one hyperbranched polyol; and (e) water.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020257 - Composition comprising a polyol, a sugar silicone surfactant and a oil-soluble polar modified polymer: The invention relates to a composition comprising a oil-soluble polar modified polymer, a sugar silicone surfactant and a hyperbranched polyol.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020256 - Composition comprising a sugar silicone surfctant and a oil-soluble high carbon polar modified polymer: The invention relates to a composition comprising a oil-soluble high carbon polar modified polymer and a sugar silicone surfactant.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020255 - Composition containing a polar modified polymer: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising at least one polar modified polymer, as well as to methods of using such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020258 - Water-in-oil (w/o) emulsion stabilized with a lipophilic emulsifier and a hydrophobically modified polysaccharide: The invention relates to a composition in the form of a water-in-oil emulsion comprising an aqueous phase dispersed in an oily phase and containing: a) at least one fatty acid ester of a polyol; and b) at least one hydrophobically modified polysaccharide chosen from inulins, celluloses and derivatives thereof, starches... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020262 - Hair conditioning composition: The present invention relates to an aqueous conditioning serum. Despite the prior art there remains the need for improved serum conditioners. Accordingly, the present invention provides a visually clear aqueous conditioning serum for the hair comprising: 50 to 95% wt. water, 0.1 to 8% wt. silicone microemulsion, 5 to 15%... Agent: Unilever Patent Group
20110020259 - Cosmetic compositions comprising a polar modified polymer and a tackifier: The invention relates to a cosmetic composition comprising at least one polar modified polymer and at least one tackifier, as well as to methods of using such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020261 - Long wear, waterproof mascara composition with water washability: The present invention is directed to a long wear, washable and waterproof eye makeup composition having a unique texture and feel including (a) at least one sugar silicone surfactant; (b) at least one oil-soluble polar modified polymer; and (c) at least one oil-soluble high carbon polar modified polymer.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020260 - Long-wear and water resistant mascara composition enhancing volume and shine: The present invention is directed to long wearing, water-resistant, color enhanced eye makeup compositions having a unique texture and contribution to volume comprising an oil-soluble polar modified polymer, a polyamine, a sugar silicone surfactant and an alkyl ethoxylated polymer wax.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020263 - Composition containing a block polymer and a nonvolatile ester oil: Composition for making up and/or caring for keratinous substances containing a block copolymer and a nonvolatile hydrocarbon ester oil.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020264 - Method and composition for the treatment of scars: A method and composition for treating healed wounds including hypertrophic scars so as to prevent scarring or reduce the size and improve the appearance of scars comprises applying to the healed wound or scar a composition comprising a fluid, film-forming carrier which may contain one or more active topical ingredients,... Agent: Frenkel & Associates
20110020265 - Use of oligomers of lactic acid in the treatment of gynaecological disorders: Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to... Agent: Edwards Angell Palmer & Dodge LLP
20110020266 - G-csf conjugates: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo... Agent: Maxygen, Inc. Intellectual Property Department
20110020267 - Tweak receptor: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac... Agent: Immunex Corporation Law Department
20110020273 - Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed... Agent: Immunomedics, Inc.
20110020272 - Combination therapy for treating hepatitis viral infection: Disclosed are methods of using proteasome inhibitors (PI) in combinations with other pharmaceutically active agents for treating viral hepatitis infections, for example, for treating therapy-resistant and -refractory viral hepatitis infections. Also disclosed are pharmaceutical compositions and kits of pharmaceutical compositions which can be used for treating viral hepatitis infections, for... Agent: Wilmerhale/boston
20110020275 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company
20110020277 - Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. I... Agent: Louis J. Wille Bristol-myers Squibb Company
20110020271 - Elastin for soft tissue augmentation: The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20110020269 - Methods and compositions for modifying t cell immune responses and inflammation: Methods and compositions for immune modulation are described herein. The compositions encompass pharmaceutical compositions that include a combination of agents. The first agent can selectively stimulate regulatory T cells or selectively inhibit inflammatory T cells and the second agent can reduce an inflammatory response in a tissue of a patient... Agent: Fish & Richardson P.C. (bo)
20110020274 - Mobilization of hematopoietic stem cells: Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more... Agent: Knobbe Martens Olson & Bear LLP
20110020276 - Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company
20110020270 - Treatment and prophylaxis: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia... Agent: Seed Intellectual Property Law Group PLLC
20110020278 - Inhibitors of flaviviridae viruses: i
20110020279 - Rabies cure: This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies... Agent: Patwrite LLC
20110020280 - Pharmaceutical composition for transnasal administration: i
20110020281 - Methods for treating a plant exposed to a phytotoxicant: Methods of treating a plant exposed to a phytotoxicant are provided. Embodiments of the subject methods include identifying a plant exposed to a phytotoxicant and applying an assimilable carbon-skeleton energy component-comprising composition to the identified plant. Embodiments of the subject compositions may include one or more of a macronutrient component,... Agent: Bozicevic, Field & Francis LLP
20110020282 - Recombinant newcastle disease virus: The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding... Agent: Millen, White, Zelano & Branigan, P.C.
20110020300 - Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a GCR gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the... Agent: Genentech, Inc.
20110020301 - Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease: The use of S-adcnosylmcthioninc (SAM) in combination with supcmxidc dismutase (SOD) for the preparation of medicaments for the treatment of Alzheimer's disease.... Agent: Lucas & Mercanti, LLP
20110020283 - Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans: A pharmaceutical composition for the prophylaxis, suppression or elimination of allergic reactions in humans, includes probiotic, gram-positive bacteria, such as, for example, Lactobacillus and Bifidobacterium as the substantial active ingredient and, more particularly, as viable bacteria, inactivated bacteria or the genomic DNA of such bacteria, or as a combination thereof.... Agent: Edwin D. Schindler
20110020285 - Composition containing cacao and spirulina: The invention relates to a composition containing cacao and spirulina, made exclusively from natural products. The composition also contains variable proportions of: royal jelly, turmeric, maca, quinoa, stevia, jojoba and argan oil. The composition can take the form of a bar, sweet or drink. The composition is a high-energy appetite... Agent: Sturm & Fix LLP
20110020284 - Probiotic bifidobacterium strains: Bifidobacterium strain AH1206 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity for example undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease.... Agent: Jacobson Holman PLLC
20110020302 - Natural preservative blend: A composition to be used as a natural preservative is provided. The composition comprises 1.0 to 20% w/w one or more naturally occurring substances containing salicylate, 0.1 to 20% w/w one or more species of lonicera, 0.1 to 80% w/w one or more leuconostoc, and 0.1 to 10% w/w gluconic... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department
20110020303 - Novel use of probiotics: The invention relates to the use of probiotics in the manufacture of a composition for enhancing a metabolic profile in a subject. The probiotics are capable of preventing and treating diseases or disorders associated with an abnormal metabolic profile, especially a lipid profile by normalizing the profile. The probiotics are... Agent: Sughrue Mion, PLLC
20110020304 - Synbiotic mixture: This invention relates to a preparation comprising N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic Lactobacillus sp. The invention extends to nutritional compositions comprising said preparation and to the use of the preparation in the prevention and treatment of pathogenic infections of the gastro-intestinal and upper respiratory tracts.... Agent: K&l Gates LLP
20110020305 - Probiotic, lactic acid-producing bacteria and uses thereof: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20110020306 - Probiotic, lactic acid-producing bacteria and uses thereof: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20110020307 - Compositions and methods for microbe storage and delivery: The present invention relates to the field of bacteriology. In particular, the invention relates to compositions of probiotic microbes and methods for making and using such compositions, e.g. in the treatment and prevention of catheter associated urinary tract infections.... Agent: Casimir Jones, S.c.
20110020286 - Trichoderma atroviride sc1 for biocontrol of fungal diseases in plants: An embodiment of the present invention is a Trichoderma atroviride SC1, CBS n° 122089, as a biocontrol agent, i.e. to treat fungal diseases of plants. The second embodiment of the present invention is an agricultural composition comprising the Trichoderma atroviride SC1 as the active principle in an effective amount. The... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP
20110020290 - Bacteriophage-containing therapeutic agents: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a... Agent: Evan Law Group LLC
20110020289 - Novel mycovirus, attenuated strain of phytopathogenic fungus, plant disease controlling agent, method of producing mycovirus, method of attenuating phytopathogenic fungus and method of controlling plant disease: The present invention provides a novel mycovirus that suppresses phytopathogenic fungi and a novel method for controlling plant diseases. A novel mycovirus that is present endogenously in a predetermined rice blast fungus, has four types of double-stranded RNAs of 2.8 to 3.6 kb, and suppresses a phytopathogenic fungus has been... Agent: Birch Stewart Kolasch & Birch
20110020287 - Parvovirus cancer therapy and combination with chemotherapy: Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral... Agent: Crowell & Moring LLP Intellectual Property Group
20110020288 - Reoviruses having modified sequences: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.... Agent: Mckeon Meunier Carlin & Curfman LLC
20110020298 - Collagen-binding synthetic peptidoglycans, preparation, and methods of use: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates... Agent: Barnes & Thornburg LLP
20110020297 - Dner-mediated cell purification of pancreatic endocrine pre-progenitor cells and their progeny: The invention relates to a method of identifying and obtaining a culture cells comprising cells selected from the group consisting of endocrine pre-progenitor cells, endocrine progenitor cells, early endocrine cells, and/or fully differentiated endocrine cells. Also contemplated is a method of expanding the number of such cells as well as... Agent: Novo Nordisk, Inc. Intellectual Property Department
20110020294 - Inducement of organogenetic tolerance for pancreatic xenotransplant: Provided herein is an approach to establish organogenetic tolerance via prior transplantation of pig embryonic pancreas, thereby enabling subsequent implantation of porcine islets in a subject without the need for immune-suppression. In one aspect of the invention, porcine pancreatic primordia are implanted into a mammalian subject, and after a period... Agent: Washington University C/o Snr Denton US LLP
20110020299 - Method and composition for the regeneration of tissue with the aid of stem cells or bone marrow cells: The invention relates to a novel polymerisable composition essentially consisting of blood or blood plasma, and also stem cells or bone-marrow cells, and to a method for tissue regeneration with the aid of such compositions. Mixtures of this type are able to polymerise under the influence of endogenous or exogenous... Agent: Arent Fox LLP
20110020296 - Methods for treating diseases and increasing longevity: Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or... Agent: Gerald K. White, Esq. Gerald K. White & Associates. P.C.
20110020295 - Pre-transplant accommodated organs resistant to anti-donor immunity: This invention includes the composition of organ grafts accommodated prior to transplantation and therefore resistant to rejection by preformed antibodies. Accommodation is achieved within the donor animal by administration of sub-lethal levels of accommodation inducing factors derived from animals sensitized to the donor.... Agent: Banner & Witcoff, Ltd.
20110020291 - Use of stem cells for wound healing: Cells, compositions, and methods of cell therapy for administering a therapeutically effective amount of stem cells or cell concentrate to achieve accelerated wound healing of normal and chronic wounds, while minimizing the formation of scar tissue.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20110020292 - Use of stem cells to reduce leukocyte extravasation: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.
20110020293 - Use of stem cells to reduce leukocyte extravasation: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.
20110020309 - Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergice disease: Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen... Agent: Philip S. Johnson Johnson & Johnson
20110020308 - Expression of transgenic t cell receptors in lak-t cells: The present invention is directed to LAK-T cells, which have been transformed by a transgenic T cell receptor (tg-TCR). The invention is further directed to a method of generating those transgenic T cells, a pharmaceutical composition comprising said cells and the use of the LAK-T cells or of the pharmaceutical... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.
20110020310 - Root canal filler and dental tissue regeneration method: Provided is a novel and creative dental tissue regeneration method for regenerating dental tissue after pulpectomy or the enlargement and cleaning of an infected root canal. After pulpectomy or the enlargement and cleaning of an infected root canal, a root canal filler (200) having an extracellular matrix (210) containing the... Agent: Knobbe Martens Olson & Bear LLP
20110020313 - Method of using and establishing an absorption rate level and a neuron firing level: A method for modulating the homeostatic relationship between various amino acid neurotransmitters in the body. The method includes modulating the rate of neuron firing using GABA, glutamate that is converted to GABA by GAD or GAD.... Agent: Knoble, Yoshida & Dunleavy
20110020312 - Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers: Methods and formulations for treating metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.... Agent: Mccarter & English, LLP Boston
20110020311 - Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy: A novel etiological hypothesis for Multiple Sclerosis (MS) is proposed describing autoimmune attack of ATP: Cob (I) alamin adenosyltransferase (ATR) thereby inhibiting synthesis of (5′-deoxy-5′-adenosyl) cobamide (referred to as 5′-deoxyadenosylcobalmin or AdoCbl) from Vitamin B12 providing a basis for therapeutic design and diagnostic methods. Pharmaceutical compositions for therapy of MS,... Agent: James Layne Boucher
20110020314 - Identifying haematopoietic stem cells based on cell surface markers: The present invention relates to a method of identifying a haematopoietic stem cell (HSC) or progeny thereof comprising the steps of: obtaining a cell sample including HSC or progeny thereof; detecting the presence of at least one carbohydrate sequence having a sequence of at least one disaccharide repeat of glucuronic... Agent: Bozicevic, Field & Francis LLP
20110020316 - Composition and method to alleviate joint pain: Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.
20110020315 - Treatment of inflammatory illnesses with ace2: The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation.... Agent: Glaxosmithkline Global Patents -us, Uw2220
20110020317 - Breast tumour grading: We describe a method of assigning a grade to a breast tumour, which grade is indicative of the aggressiveness of the tumour, the method comprising detecting the expression of a gene selected from the genes set out in Table D1 (SWS Classifier 0).... Agent: Wilmerhale/new York
20110020324 - Compound capable of binding s1p receptor and pharmaceutical use thereof: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1,... Agent: Sughrue-265550
20110020322 - Crystallization of anti-cd20 antibodies: The present invention relates generally to crystalline forms of anti-CD20 antibodies and purification of anti-CD20 antibodies involving crystallization.... Agent: Genentech, Inc.
20110020320 - Genetic variants contributing to risk of prostate cancer: It has been discovered that certain genetic markers are associated with risk of prostate cancer. The invention describes diagnostic applications for determining a susceptibilty to prostate cancer using such markers, including methods, uses, kits, and computer applications.... Agent: Marshall, Gerstein & Borun LLP
20110020323 - Gram-positive bacteria specific binding compounds: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.... Agent: Morrison & Foerster LLP
20110020318 - Inhibitors of the interaction between hmgb polypeptides and toll-like receptor 2 as anti-inflammatory agents: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20110020326 - Method of treating polycystic kidney disease: The present invention is directed toward methods for treating, inhibiting the progression of or eradicating polycystic kidney disease in a mammal in need thereof by providing a cMET inhibitor.... Agent: David S. Resnick
20110020321 - Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor: Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor,... Agent: Law Office Of John K. Pike, PLLC
20110020325 - Methods for reducing granulomatous inflammation: This document provides methods and materials for reducing bacterial induced granulomatous inflammation in a mammal using agents that reduce B7-H1 expression or activity.... Agent: Fish & Richardson P.C. (tc)
20110020319 - Use of anti- sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents: The present invention relates to use of anti-S1P antibodies in combination with chemotherapeutic agents for treatment and/or prevention of cancer, tumor growth, metastasis and/or growth of metastatic tumors.... Agent: Biotechnology Law Group 12707 High Bluff Drive
20110020338 - 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes: in the treatment of mammalian target of VEGF-driven angiogenic diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said... Agent: Novartis Corporate Intellectual Property
20110020333 - Angiogenesis pathway gene polymorphisms for therapy selection: A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein... Agent: Foley & Lardner LLP
20110020328 - Antibody formulations: This invention relates to a shear and temperature stable antibody formulations that are more stable than compared to a standard formulation (such as 30 mM citrate, 100 mM NaCl, pH 6.5). The present invention's shear and temperature stable antibody formulations show reduced precipitation when subjected to stress conditions but the... Agent: Glaxosmithkline Global Patents -us, Uw2220
20110020330 - Antibody inhibitors of gdf-8 and uses thereof: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.... Agent: Wyeth LLC/finnegan Henderson, LLP
20110020336 - Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection: The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20110020329 - Conjugates of anti-rg-1 antibodies: Anti-RG-1 antibodies, antibody fragments, or antibody mimetics conjugated to partner molecules, such as drugs, radioisotopes, and cytotoxins, wherein the partner molecule exerts its effect regardless of whether the RG-1 bound conjugate is internalized within a targeted cell, are useful for treating cancers.... Agent: Medarex, Inc.
20110020334 - Methods for treating and preventing brain tumors based on bone morphogenetic proteins: The present invention is concerned with the therapy of neuroblastoma and related diseases. Specifically, the present invention relates to a method for treating or preventing neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4). Preferably, said BMP4 is applied together with chemotherapy and/or... Agent: Birch Stewart Kolasch & Birch
20110020337 - Methods for treating conditions associated with masp-2 dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2... Agent: Christensen, O'connor, Johnson, Kindness, PLLC
20110020339 - Methods of treatment: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or... Agent: Glaxosmithkline Global Patents -us, Uw2220
20110020331 - N-glycosylated antibody: The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected... Agent: Birch Stewart Kolasch & Birch
20110020332 - Prevention of tumors with monoclonal antibodies against neu: Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its... Agent: Cooper And Dunham LLP
20110020327 - Purification of proteins: The present invention relates to a bimodal polymer such as a soluble polymer capable of irreversibly binding to insoluble particulates and a subset of soluble impurities and also capable of reversibly binding to one or more desired biomolecules in an unclarified biological material containing stream and the methods of using... Agent: Millipore Corporation
20110020335 - Treatment of cancers expressing p95 erbb2: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an... Agent: Glaxosmithkline Global Patents
20110020340 - Antibody-light fusion products for cancer therapeutics: Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.... Agent: Barnes & Thornburg LLP
20110020343 - Auristatin drug linker conjugates: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.... Agent: Seattle Genetics, Inc.
20110020345 - Drug fusions and conjugates: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.... Agent: Glaxosmithkline Global Patents -us, Uw2220
20110020344 - Human monoclonal antibodies specific for cd22: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can... Agent: Klarquist Sparkman, LLP (ott-nih)
20110020342 - Igf-1 fusion polypeptides and therapeutic uses thereof: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain... Agent: Regeneron Pharmaceuticals, Inc
20110020341 - Novel multidrug resistance-associated polypeptide: Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-β. The disclosed... Agent: Mccarter & English, LLP Boston
20110020346 - Anti-vegf antibodies: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in... Agent: Clark & Elbing LLP
20110020357 - Anti human immunodeficiency antibodies and uses thereof: Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with a human immunodeficiency virus (HIV) peptide, wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide, and wherein the antibody does not bind the peptide in an... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.
20110020347 - Anti-brak (cxcl14) human monoclonal antibody and use thereof: Disclosed is an antibody which can recognize BRAK (CXCL14). Also disclosed is use of the antibody. The antibody can recognize a polypeptide comprising an amino acid sequence depicted in SEQ ID NO:1 or 2, a derivative thereof, or a partial peptide of the polypeptide or the derivative.... Agent: Ladas & Parry LLP
20110020349 - Anti-factor xi monoclonal antibodies and methods of use thereof: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments,... Agent: Klarquist Sparkman LLP
20110020353 - Antibodies and related molecules that bind to 161p2f10b proteins: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B... Agent: Agensys C/o Morrison & Foerster LLP
20110020350 - Contraceptives based on sp22 and sp22 antibodies: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.... Agent: Foley Hoag, LLP (w/isa) Patent Group
20110020352 - Endogenous retroviruses up-regulated in prostate cancer: Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.... Agent: Novartis Vaccines And Diagnostics Inc.
20110020354 - G-protein coupled receptor ligands and methods: The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.... Agent: Merck Patent Department (k-6-1, 1990)
20110020351 - Novel polypeptide esdn, polynucleotides encoding the polypeptide, and utility of the polypeptide: The invention discloses a useful and novel factor (polypeptide) which plays an important role for morbid vascular smooth muscle in restenosis after percutaneous transluminal coronary angioplasty (PTCA) and arterial sclerosis in the field of cardiovascular system.... Agent: Sughrue Mion, PLLC
20110020348 - Pharmaceutical compositions and methods using secreted frizzled related protein: Pharmaceutical compositions and methods of use in regulation of mammalian bone forming activities of sFRPs (secreted frizzled-related proteins) are disclosed. sFRPs are secreted receptors for Wnts, which are important polypeptide growth factors that are known to regulate fundamental biological processes like tissue polarity, embryonic development, and tumorigenesis. A sFRP was... Agent: Wyeth LLC Patent Law Group
20110020356 - Therapeutic clostridium difficile antibody compositions: The C. difficile proteins Cwp84, FliC and FliD, known to have conserved peptide sequences, were separately injected into female chickens, and the antibody rich egg yolks harvested. The antibody compositions were then titered by ELISA and western immunoblotting. Anti-FliD IgY, anti-Cwp84 IgY, and an equititer cocktail of the three IgY... Agent: Robert W.b. Bailey
20110020355 - Treatment and prevention of gardnerella vaginalis infections: The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments... Agent: Ditthavong Mori & Steiner, P.C.
20110020358 - Methods and compositions for detecting amyotrophic lateral sclerosis: The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.
20110020359 - Methods and compositions for treating neuronal damage or degeneration: This invention provides methods and compositions for reducing chondroitin-sulfate-proteoglycan-mediated inhibition of neuronal growth. The methods and compositions provided herein are particularly useful for treatment of neuronal damage or degeneration.... Agent: Wilson, Sonsini, Goodrich & Rosati
20110020361 - Human anti-mesothelin monoclonal antibodies: Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can... Agent: Klarquist Sparkman, LLP (ott-nih)
20110020360 - Targeted binding agents directed to pdgrf-alpha and uses thereof: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such... Agent: Astrazeneca
20110020362 - Adrenergic stimulation mediates hypersensitivity by inducing nerve growth factor expression: The current invention provides mechanisms by which chronic stress induced hypersensitivity exacerbates the symptoms of irritable bowel syndrome. The invention includes methods of treating irritable bowel syndrome using agents which inhibit key molecules involved in the sensitization pathway.... Agent: Benjamin Aaron Adler Adler & Associates
20110020365 - Methods and compositions for identifying, diagnosing, and treating neuroblastoma: Methods and compositions for identifying, diagnosing, and treating neuroblastoma are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman
20110020364 - Methods and compositions involving pbef inhibitors for lung inflammation conditions and diseases: The present invention concerns methods and compositions involving inhibitors of Pre-B Cell Colony Enhancing Factor (PBEF) for inflammatory conditions and diseases, including acute lung injury (ALI), ventilator-induced lung injury (VILI), and acute respiratory distress syndrome (ARDS). The present invention also concerns biomarkers for inflammation as well as methods for screening... Agent: Fulbright & Jaworski L.L.P.
20110020363 - Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13ralpha1): The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of... Agent: Scully Scott Murphy & Presser, PC
20110020366 - Use of benzophenone derivative or salt thereof and tnf alpha inhibitor in combination and pharmaceutical composition containing the derivative or salt thereof and the inhibitor: Disclosed are a use of a benzophenone derivative or a salt thereof and one or more TNFα inhibitors in combination, and a pharmaceutical composition containing the benzophenone derivative or a salt thereof and one or more TNFα inhibitors. The use and the composition are useful for treatment or prevention of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110020367 - Methods of evaluating transplant rejection: The invention relates to methods of evaluating transplant rejection in a host comprising determining a heightened magnitude of gene expression of genes in rejection-associated gene clusters. The disclosed gene clusters include genes that are substantially co-expressed with cytotoxic lymphocyte pro-apoptotic genes, cytoprotective genes and several other cytokine and immune cell... Agent: Fish & Richardson P.C. (bo)
20110020368 - Treating cancer by down-regulating frizzled-4 and/or frizzled-1: The present invention relates to a method for treating cancer, for instance breast cancer, in a subject by inhibiting Frizzled-4 and/or Frizzled-1 by administering to said subject a therapeutically effective amount of a modulator of Frizzled-4 and/or Frizzled-1, for example a specific antibody or a siRNA.... Agent: Novartis Corporate Intellectual Property
20110020369 - Engineered anti-tslpr antibodies: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.... Agent: Merck Patent Department (k-6-1, 1990)
20110020370 - Slc7a5 directed diagnostics and therapeutics for neoplastic disease: Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of SLC7A5 in the test cell sample or fluid sample as compared to the level of expression of SLC7A5 in a control cell sample or fluid sample... Agent: Wilmerhale/boston
20110020371 - Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery: The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting... Agent: Davis Wright Tremaine LLP/los Angeles
20110020372 - Follistatin domain containing proteins: The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that... Agent: Wyeth LLC/finnegan Henderson, LLP
20110020373 - Ige directed dna vaccination: This invention is directed to a novel approach for focusing and expressing DNA vaccinates in Antigen Presenting Cells (APCs) mediated through targeting IgE receptors (FcεRs) on APC and driving DNA expression through provision of an APC specific regulatory element This vaccine can be used in the prevention or treatment of... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.
20110020376 - Aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent: Vertex Pharmaceuticals Inc.
20110020377 - Aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent: Vertex Pharmaceuticals Inc.
20110020374 - Expression system for modulating an immune response: The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least... Agent: Seed Intellectual Property Law Group PLLC
20110020378 - Self-assembling peptide nanoparticles useful as vaccines: Self-assembling peptide nanoparticles (SAPN) incorporating T-cell epitopes and/or B-cell epitopes are described. The nanoparticles of the invention consist of aggregates of a continuous peptidic chain comprising two oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate T-cell epitopes and/or B-cell epitopes within their peptide sequence.... Agent: Wenderoth, Lind & Ponack, L.L.P.
20110020375 - Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use: Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such... Agent: Fiveprime/finnegan
20110020379 - Cobalamin assay: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.... Agent: Bacon & Thomas, PLLC
20110020380 - Human tumor necrosis factor tr18 and methods based thereon: The present invention relates to TR18 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR18 protein. TR18 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR18... Agent: Human Genome Sciences Inc. Intellectual Property Dept.
20110020381 - Influenza vaccine formulation: Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza.... Agent: Borden Ladner Gervais LLP Anne Kinsman
20110020385 - Combinations of pneumococcal rrgb clades: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic... Agent: Novartis Vaccines And Diagnostics Inc.
20110020383 - Novel genes and proteins of brachyspira hyodysenteriae and uses thereof: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of... Agent: Christensen, O'connor, Johnson, Kindness, PLLC
20110020382 - Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Wyeth LLC Patent Law Group
20110020384 - Therapeutic tb vaccine: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.... Agent: Howson & Howson LLP
20110020386 - Vaccines and compositions against streptococcus pneumoniae: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.... Agent: Ropes & Gray LLP Iprm - Floor 43
20110020387 - Malaria vaccine: A fusion protein, from P. falciparum Glutamate-rich protein (GLURP) genetically coupled to P. falciparum Merozoite surface protein 3 (MSP3) was produced in Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein... Agent: Knobbe Martens Olson & Bear LLP
20110020388 - Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents: This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that... Agent: Selecta Biosciences, Inc. C/o Wolf, Greenfield, & Sacks, P.C.
20110020389 - Agents for promoting secretion and/or suppressing decrease of adiponectin: To provide an agent promoting secretion and/or suppressing decrease of adiponectin, and an eating and drinking product and a feed promoting secretion and/or suppressing decrease of adiponectin. Provided are an agent promoting secretion and/or suppressing decrease of adiponectin, and a eating and drinking product and a feed promoting secretion and/or... Agent: Greenblum & Bernstein, P.L.C
20110020390 - Meningococcal fhbp polypeptides: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a... Agent: Novartis Vaccines And Diagnostics Inc.
20110020391 - Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament in particular a vaccine, wherein the sequence of heterologous nucleic acid is from influenza A virus class H5 antigen. In a further aspect of... Agent: Millen, White, Zelano & Branigan, P.C.
20110020393 - Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine: The present inventors improved methods for inactivating Japanese encephalitis virus vaccines, and assessed the safety of vaccines produced by combining multiple vaccines. The present inventors successfully produced safer Japanese encephalitis vaccines by cell culture, which can be stored more stably over a long period than conventional Japanese encephalitis vaccines. Furthermore,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20110020392 - Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as RA, Tremors/Parkinson's Disease, and MS, and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from RA, MS, Tremors/Parkinson's Disease,... Agent: Dergosits & Noah LLP
20110020394 - Pcv2 orf2 virus like particle with foreign amino acid insertion: The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, PCV2 ORF2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the DNA encoding the PCV2 ORF2 is inserted... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20110020395 - Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings: The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of off-spring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expecting females can induce a better protection... Agent: K&l Gates LLP
20110020396 - Hiv envelope-cd4 complexes and hybrids: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.... Agent: Novartis Vaccines And Diagnostics Inc.
20110020397 - Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry... Agent: Townsend And Townsend And Crew, LLP
20110020398 - Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis c virus: The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.... Agent: Clark & Elbing LLP
20110020400 - Probiotic bifidobacterium strains: Probiotic Bifidobacterium strain AH1205 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity such as undesirable gastrointestinal inflammatory activity for example inflammatory bowel disease.... Agent: Jacobson Holman PLLC
20110020401 - Tissue targeted antigenic activation of the immune response to treat cancers: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate... Agent: Bozicevic, Field & Francis LLP
20110020399 - Vaccines and immunomodulatory therapies for tularemia: The present invention relates to attenuated strains of Francisella tularensis from which genes in the guanine nucleotide biosynthetic pathway have been deleted and to methods for making the mutants. The invention further relates to the use of the attenuated strains to make vaccines.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.
20110020402 - Method for identification, isolation and production of antigens to a specific pathogen: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized... Agent: Fulbright & Jaworski L.L.P.
20110020403 - immunizing composition: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against... Agent: Birch Stewart Kolasch & Birch
20110020404 - Diagnostic method and kit: The invention relates to methods for diagnosis of tuberculosis in an animal, the methods comprising determining the presence or absence of, or an immune response to a group of antigens comprising (i) the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, and ESAT 6 antigen; or (ii) at least... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20110020405 - Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant: The invention relates to composition comprising a RPE and optionally a Th1-promoting adjuvant for the preparation of a medicament for the treatment or prevention of a parasitic disease and to its use.... Agent: Browdy And Neimark, PLLC
20110020406 - Viral inactivation process: The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the effect of a viral inactivation procedure on the antigenicity of the inactivated virus. In particular for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae,... Agent: Traskbritt, P.C.
20110020408 - multilayered modified release formulation comprising amoxicillin and clavulanate: The present invention relates to multilayered modified release formulation comprising amoxicillin and clavulanate, process of preparation thereof and method of treating bacterial infection using these formulations. The multilayered modified release formulation comprises: an immediate release layer comprising amoxicillin and clavulanate; and a slow release layer comprising amoxicillin and one or... Agent: Ranbaxy Inc.
20110020411 - Factor replacement therapy: The present invention provides compositions and methods for providing factor replacement therapy. In particular, the present invention provides replacement therapy for subjects suffering from cystinosis.... Agent: Casimir Jones, S.c.
20110020412 - Novel dosage and formulation: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110020409 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.
20110020410 - Stable solid preparations: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming... Agent: Hamre, Schumann, Mueller & Larson, P.C.
20110020407 - Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy: Transdermal therapeutic system with which at least one pharmaceutical active substance that is non-volatile at room temperature can be administered at a daily dose of at most 30 mg, comprising a rear surface directed away from the skin and impermeable to the active substance, an adjoining polymer layer located away... Agent: Frommer Lawrence & Haug
20110020417 - Chewing gum: A novel chewing gum is provided which gives a strong coolness feeling and excellent mouth feeing in chewing. The chewing gum contains particles of one or more of crystalline matter selected from the group consisting of erythritol, xylitol, and sorbitol in an amount ranging from 5% to 70% by weight... Agent: Miles & Stockbridge PC
20110020415 - Composition for treatment of hyperhidrosis: A composition for treatment of hyperhidrosis is provided that contains an effective amount of an antiperspirant. In particular, one embodiment of the composition of the present invention includes an antiperspirant, at least one muscle relaxing agent, at least one peptide, and at least one botanical agent and the composition is... Agent: Husch Blackwell LLP
20110020416 - Encapsulated fragrance materials and methods for making same: The present invention is directed to novel capsules containing active materials and methods for making capsules with enhanced performance and stability. The capsules are well suited for use in personal care applications, laundry products and perfume and fragrance products.... Agent: Elizabeth M. Quirk, Esq. International Flavors & Fragrances Inc.
20110020414 - Moisturizing retinol composition: An anti-aging composition is provided that contains high potency retinol along with anti-irritant properties. In particular, an anti-aging composition includes a base, from about 0.001% to 20.0 vol % retinol, at least one anti-irritant agent, at least one antioxidant, at least one anti-inflammatory agent, and a moisturizing complex. In one... Agent: Husch Blackwell LLP
20110020413 - Polysilsesquioxane compositions and process: Composite particles comprised of an optical agent(s) entrapped in a non-porous microparticle of polyorganosilsesquioxane to yield discrete microparticles, are provided. The optical agent is fully encapsulated in the interior of the silsesquioxane particle to impart optical properties that include absorption and emission in the ultraviolet and visible spectrum respectively, without... Agent: Kf Ross PC
20110020418 - Particulate tissue graft with components of differing density and methods of making and using the same: Disclosed are tissue graft compositions made of particles having different densities, methods of making these compositions, and methods of using these compositions for promoting tissue restoration in a patient.... Agent: Burns & Levinson, LLP
20110020421 - Biodegradable polyphosphazenes containing pyrrolidone side groups: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi
20110020422 - Hydroxyapatite-targeting poly(ethylene glycol) and related polymers: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a... Agent: Nektar Therapeutics
20110020419 - Osteoinductive calcium phosphates: The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 μm, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 μm, and having a surface area percentage of micropores in a range of 10-40%.... Agent: Morrison & Foerster LLP
20110020420 - Variable density tissue graft composition and methods of making and using the same: Disclosed are tissue graft compositions made of materials having different densities, methods of making, and methods of treatment for restoring tissues in a patient.... Agent: Burns & Levinson, LLP
20110020423 - Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.... Agent: Covington & Burling, LLP Attn: Patent Docketing
20110020425 - Materials and methods for wound treament: The subject invention pertains to methods and compositions for wound treatment. The methods and compositions provide for promoting and accelerating wound healing; provide for inhibition of microbial infection; provide for a protective scab-like covering on a wound; and/or for arresting the flow of blood or body fluids from an open... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20110020424 - Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds: The invention provides oleocanthal analogs and methods of using oleocanthals in various formulations including, food additives; pharmaceuticals; cosmetics; animal repellants; and discovery tools for mammalian irritation receptor genes, gene products, alleles, splice variants, alternate transcripts and the like.... Agent: Woodcock Washburn LLP
20110020426 - Process for the continuous manufacture of a polyisobutylene based transdermal patch: The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer... Agent: Lerner, David, Littenberg, Krumholz & Mentlik
20110020431 - Antitumor effect of mutant bik: The present invention regards mutant forms of Bik that comprise anti-cell proliferation and/or pro-apoptotic activities. In particular embodiments, the Bik polypeptides comprise a substitution at Thr33 and Ser35 and, in some embodiments, phosphorylation at these sites is inhibited. In more particular embodiments, these forms are useful for cancer therapy, particularly... Agent: Fulbright & Jaworski, LLP
20110020432 - Compositions and methods of use for post-radiation protection: The present disclosure is directed to methods of administering RL1P76 or an active fragment thereof more than 24 hours after radiation exposure, wherein administration is effective for the protection and treatment of mammals exposed to radiation. In addition, compositions are disclosed including RLIP76 and other radioprotective agents, for example antioxidants.... Agent: Dla Piper LLP (us)
20110020433 - Compositions for delivery of cargo such as drugs proteins and/or genetic materials: Compositions and methods for delivery of cargo molecules to a patient or subject in need thereof include a proteoliposome carrier vehicle that incorporates an RLIP76 protein and contains the cargo molecule. The vehicle effectively delivers the cargo molecule systemically throughout the tissues of the body including into the central nervous... Agent: Dla Piper LLP (us)
20110020428 - Gel-stabilized liposome compositions, methods for their preparation and uses thereof: Compositions, preparation methods and potential applications of gel-stabilized liposomes with high degree of entrapment efficiency and stability are described. In particular, the novel liposome system comprises liposomes that each encapsulate an internal thermo-transformable hydrogel, dispersed and suspended in a continuous external thermo-reversible hydrogel phase. Agents, such as active agents, are... Agent: Bell & Manning, LLC
20110020427 - Method of treating malignant solid tumors using transcatheter arterial chemoembolization (tace): This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the... Agent: Squire, Sanders & Dempsey LLP
20110020434 - Nanoparticle arsenic-platinum compositions: The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.... Agent: Casimir Jones, S.c.
20110020430 - Novel mrna splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy: Methods for treating neuroblastoma in a subject are provided. The methods include administering to the subject nucleic acid that is capable of causing a significant reduction of the amount of doublecortin like protein (DCL) in the subject. The nucleic acids include antisense oligonucleotides and small interfering RNA.... Agent: Young & Thompson
20110020437 - Oligopeptidic compounds and uses thereof: The present invention provides an oligopeptidic compound comprising a PCNA interacting motif, or a nucleic acid molecule comprising a sequence encoding said oligopeptidic compound, for use in therapy, wherein the PCNA interacting motif is X1X2X3X3′X1′″ (SEQ ED NO: 1), wherein X1 and X1′″ are independently selected from the group of... Agent: Knobbe Martens Olson & Bear LLP
20110020435 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of insulin or an analog thereof.... Agent: Dla Piper LLP (us)
20110020436 - Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes: The invention is a topical therapeutically effective amount of melatonin encapsulated in a liposome applied topically to an area of skin affected by immunologic response, radiation treatment induced dermatitis, acne, insect bite or other irritant stimulus such as sunburn in order to reduce itching. The invention also proposes a topical... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al
20110020429 - Use of particles comprising an alcohol: Novel use of ultrasound sensitive drug carrying particles comprising an alcohol is disclosed, as well as products and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon ultrasound exposure.... Agent: Birch Stewart Kolasch & Birch
20110020438 - Crystallization inhibitor and its use in gelatin capsules: The present invention describes soft gelatin capsules that encapsulate a water-insoluble active ingredient and an excipient composed of a crystallization inhibitor that stabilizes the water-insoluble inhibitor. The crystallization inhibitor being at least one mononacylglycerol compound whose acyl group is a fatty acid residue of 6-18 carbon atoms. The capsule contents... Agent: Lerner, David, Littenberg, Krumholz & Mentlik
20110020439 - Delayed release compositions of duloxetine: A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof; intermediate layer; and enteric layer; wherein the dosage form comprises one/more dissolution enhancer(s), wherein the enteric layer comprises one/more enteric polymers other than hydroxypropylmethyl acetate succinate. A... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket
20110020440 - Stable solutions of sparingly soluble actives: The present invention relates to a stable pharmaceutical composition comprising soft gelatin capsules containing at least one sparingly soluble active drug (singly or in combination with sparingly soluble and/or soluble drugs) and a solvent system, wherein the solvent system comprises of solvent, co-solvent, solubilizer(s), surfactant, aqueous solution of alkali and... Agent: Pepper Hamilton LLP
20110020442 - Taste masked oral composition of telithromycin: The invention relates to an oral compositions comprising telithromycin that have taste masking properties, a process for the preparation thereof, and methods of using the composition.... Agent: Scully, Scott, Murphy & Presser, P.C.
20110020441 - Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis: The present invention relates to the use of a photosensitiser which is 5-ALA or a precursor or derivative thereof (e.g. an ALA ester), in the manufacture of a pharmaceutical product for use in the photodynamic treatment or diagnosis of cancer, an infection associated with cancer, or in the treatment or... Agent: Kenyon & Kenyon LLP
20110020444 - Abuse-resistant opioid dosage form: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.... Agent: Ip Group Of Dla Piper LLP (us)
20110020443 - Slow release magnesium composition and uses thereof: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side... Agent: Wilson, Sonsini, Goodrich & Rosati
20110020445 - Extended release pharmaceutical compositions of levetiracetam: Extended release pharmaceutical compositions of levetiracetam or pharmaceutically acceptable salts thereof in the form of a tablet comprising glyceryl behenate and a polymethacrylate polymer with at least one pharmaceutically acceptable excipient.... Agent: Hiscock & Barclay, LLP
20110020446 - Methods and formulations for making pharmaceutical compositions containing bupropion: Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating.... Agent: Patterson & Sheridan, L.L.P.
20110020447 - Novel dosage form: The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Global Patents
20110020449 - Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives: Pain or irritation of the eyes, caused by injury due to dry eye syndrome, chemical burns or the like can be accompanied by corneal stromal edema. It has been discovered that administration of thymosin β4 and/or oxidized thymosin β4 to cornea in need of treatment of corneal stromal edema is... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20110020448 - Pharmaceutical composition for the treatment and prevention of glaucoma: Provided is a pharmaceutical composition for the treatment and prevention of glaucoma, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.... Agent: Ladas & Parry
20110020450 - Titratable dosage transdermal delivery system: The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more... Agent: Jones Day
20110020451 - Tamper-resistant dosage form for oxidation-sensitive opioids: e
20110020452 - Progenitor cell replication and differentiation in 3d: The present invention is directed to a new approach towards in situ differentiation of tissue progenitor cells, without the coventional requirements of weeks of cellular manipulation and treatment. Such approach circumvents the need for 2D culturing and differentiation of tissue progenitor cells before implanting in a 3D biocompatible matrix, thus... Agent: Snr Denton US LLP
20110020456 - Lanthanum composition: e
20110020454 - Novel dosage and formulation: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110020455 - Solid dispersion and pharmaceutical composition of the same, and production processes thereof: A powdery porous carrier comprising a porous silicon-containing carrier is impregnated with a solution containing an organic solvent and an active ingredient hardly soluble in water, and the organic solvent is removed to give a solid dispersion having the active ingredient supported to the porous carrier without a treatment with... Agent: Wenderoth, Lind & Ponack, L.L.P.
20110020453 - Topical formulations comprising ion channel modulators: p
20110020457 - Polymer-surfactant nanoparticles for sustained release of compounds: A polymer-surfactant nanoparticle formulation, using the anionic surfactant aerosol OT (AOT) and polysaccharide polymer alginate, is used for sustained release of water-soluble drugs. The AOT-alginate nanoparticles are suitable for encapsulating doxorubicin, verapamil and clonidine, as well as therapeutic agents effective against dermal conditions such as psoriasis. The nanoparticles are also... Agent: Douglas Gergich Intellectual Property Docketing Department
20110020458 - Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.... Agent: Sughrue Mion, PLLC
20110020460 - Gpr 119 modulators: Compounds of Formula I that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.... Agent: Pfizer Inc. Patent Department
20110020459 - Microfluidic method and system for isolating particles from biological fluid: The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the... Agent: Schox PLC
20110020461 - Hyaluronate and colostrum compositions and methods of using the same: The present disclosure includes disclosure of various embodiments of composition comprising a therapeutically-effective amount of a hyaluronate and a therapeutically-effective amount of colostrum. In at least one embodiment, the hyaluronate comprises sodium hyaluronate, and the colostrum comprises bovine colostrum. In an exemplary method of reducing osteoblastic activity within a warm-blooded... Agent: Ice Miller LLP
20110020462 - New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly... Agent: Wpat, PC Intellectual Property Attorneys
20110020463 - Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain caused by muscle spasm: A therapeutic agent for fibromyalgia syndrome or therapeutic agent for pain caused by vascular smooth muscle spasm including a) one or more compounds selected from a group consisting of RNA, ribonucleotide and ribonucleoside, b) one or more compounds selected from a group consisting of L-arginine, L-citrulline and L-ornithine, and c)... Agent: Oliff & Berridge, PLC
20110020465 - Methods of treatment of gout using thymus-derived compositions: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to arthritis and/or arthritis-related... Agent: Davis Wright Tremaine, LLP/seattle
20110020464 - Methods of treatment using thymus-derived compositions: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to impaired physical vigor... Agent: Davis Wright Tremaine, LLP/seattle
20110020466 - Fertilized egg isolate and use thereof: Fertilized egg isolate, methods for preparing the fertilized egg isolate and uses thereof for treating mental health disorders and disease or conditions mediated by or associated with one or more glutamate receptors or by the neurokinin 2 (NK2) receptor.... Agent: Wilmerhale/boston
20110020467 - Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB.... Agent: Cp / Baker & Mckenzie LLP
20110020468 - Silver oxide formulations having improved whiteness characteristics: A topical formulation for application to exposed body tissue, the formulation comprising a silver(II) oxide and zinc oxide, intimately dispersed within a carrier medium.... Agent: Perry Antelman
20110020469 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Inc.
20110020470 - Methods and compositions for treating cancer: In one aspect the present invention provides methods for treating cancer in a mammal, including the step of administering to a mammal suffering from a cancer an amount of ebselen that is sufficient to inhibit the growth of the cancer. In another aspect, the present invention provides methods for enhancing... Agent: Christensen, O'connor, Johnson, Kindness, PLLC
20110020471 - Erythrocyte atp-release modulators: Erythrocyte ATP-release modulators and composition and methods for their use to potentiate serum glucose clearance and vasodilation; methods for prophylactic or palliative therapy of glucose processing or vascular disorders; processes for preparing the modulators and compositions comprising them; and kits therefor.... Agent: Harness, Dickey & Pierce, P.L.C
20110020472 - Non-aqueous generation of chlorine dioxide: Disclosed is a method of making a non-aqueous chlorine dioxide solution by combining a chlorite salt and a non-aqueous carboxylic acid and the non-aqueous chlorine dioxide solution made by this method. Also disclosed are methods of disinfecting an object by applying the non-aqueous chlorine dioxide solution to the object and... Agent: Diversey, Inc.
20110020473 - Chlorine dioxide solution composition: There are provided a chlorine dioxide solution composition whose solute includes dissolved chlorine dioxide and chlorite; and a solution composition encapsulating body including a glass vessel or enameled vessel and the chlorine dioxide solution composition hermetically sealed therein.... Agent: Buchanan, Ingersoll & Rooney PC
20110020474 - Methods of treating infections of the nail or skin using hypohalite: The present application discloses a method of treating or preventing an infection of a nail, claw, hoof, or skin comprising administering a pharmaceutically acceptable formulation comprising hypohalite and a formulating agent to a subject in need thereof, and compositions thereof.... Agent: Hamilton Desanctis & Cha, LLP
20110020475 - Cardioplegic solution: The present invention relates to a new cardioplegic solution to arrest and protect the heart muscle during surgery. The cardioplegic solution according to the invention offers several significant advantages as compared to standard available solutions, and contains magnesium sulfate heptahydrate, potassium chloride, procaine hydrochloride and xylitol.... Agent: Nixon & Vanderhye, PC
20110020476 - Composition based on vegetal extracts of ajuga reptans for preventing hair loss, stimulating the growth of hair, regulating the production of sebum: The present invention relates to preparations based on vegetal extracts of Ajuga reptans for favouring the growth of hair and stimulating the hair bulb. The preparations of the invention are in suitable formulations for oral administration or local application and are specifically suitable for the prevention and treatment of androgenic... Agent: Hedman & Costigan, P.C.
20110020477 - Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles: Wrinkles are improved by applying an oral preparation, injection preparation or external skin preparation having a substance that controls heparanase as an active ingredient thereof.... Agent: Foley And Lardner LLP Suite 500
20110020478 - Method for treating neural injuries: A method for treating neural damage with a composition prepared from roots of bupleurum and scutellaria.... Agent: Occhiuti Rohlicek & Tsao, LLP
20110020479 - Methods for modulating eicosanoid metabolism: The inventive subject matter relates to methods for modulating an eicosanoid metabolic process in cells of an animal in need thereof, which comprises administering to the animal an amount of the inventive compositions effective for regulating the activity of an eicosanoid oxygenase. In particular, the inventive subject matter relates to... Agent: The Nath Law Group
20110020480 - Use of benzoxazinoids-containing cereal grain products for health-improving purposes: The invention relates to the use of benzoxazinoids-containing grains of cereals for the production of food and beverage products with health-improving effects. Especially the invention relates to the use of benzoxazinoids-containing grains of cereals for the production of bread baked on rye grains, wheat, spelt, rye and/or spelt sprouts for... Agent: The Nath Law Group
20110020481 - Swinglea glutinosa leaves derived material in combination with avermectins for control of acari: The invention of the present application provides a natural material derived from Swinglea glutinosa leaves that in combination with avermectins, increases the effect of avermectins over mites. The material derived from Swinglea glutinosa leaves, in a preparation with avermectins, results in an all natural material with the potential to replace... Agent: John J. Martinez Md. Jd.01/20/2011 > 193 patent applications in 105 patent subcategories. recently filed with US Patent Office
20110014117 - Anti-igf1r: The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.... Agent: Merck Patent Department (k-6-1, 1990)
20110014118 - Nanotherapeutic colloidal metal compositions and methods: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor,... Agent: Johnson & Associates
20110014119 - Methods for manipulating phagocytosis mediated by cd47: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP
20110014120 - Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging: The present invention relates to trifunctional imaging agents that include an antibody for cell targeting, as well as a chelating moiety for sequestering radioisotopes and a fluorescing moiety for imaging. The invention also provides methods using the conjugates for medical diagnostic imaging.... Agent: Leydig, Voit & Mayer, Ltd.
20110014121 - Modulators of cxcr7: or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with... Agent: Townsend And Townsend And Crew, LLP
20110014122 - Novel anti-igf-ir and/or anti-insulin/igf-i hybrid receptors antibodies and uses thereof: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as... Agent: Buchanan, Ingersoll & Rooney PC
20110014125 - Protease assay: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence... Agent: Hovey Williams LLP
20110014123 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20110014124 - Targeted atherosclerosis treatment: This invention relates generally to methods for ameliorating at least one symptom or aspect of atherosclerosis. The methods include administration of targeted carrier compositions comprising a therapeutic agent effective in ameliorating at least one aspect of atherosclerosis coupled to a targeting ligand effective is targeting the therapeutic agent to tissue... Agent: Morrison & Foerster LLP
20110014128 - Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same: The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining... Agent: Choate, Hall & Stewart LLP
20110014127 - Methods for measuring a patient response upon administration of a drug and compositions thereof: Described herein are methods for effectively and accurately measuring a patient response upon administration of one or more drugs to the patient. The methods are more sensitive than current methodologies. Also described herein are compositions comprising an analgesic and a sufficient amount of an antihistamine to enhance the analgesic properties... Agent: Gardner Groff Greenwald & Villanueva. PC
20110014126 - Use of vitamin d receptor agonists and precursors to treat fibrosis: This application relates to methods of treating, preventing, and ameliorating fibrosis, such as fibrosis of the liver. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment... Agent: Klarquist Sparkman, LLP
20110014129 - Magnetic microstructures for magnetic resonance imaging: The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS... Agent: National Institutes Of Health C/o Polsinelli Shugart PC
20110014130 - Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing: The present invention provides a method for treating a solid dosage form to improve the printability and abrasion resistance of a print to be produced on a surface of the solid dosage form, which includes treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution before... Agent: Foley And Lardner LLP Suite 500
20110014131 - Nanomolding micron and nano scale features: Small scale and nanoscopic identification features can be fabricated for pharmaceutical capsules. A composition comprising a capsule component, wherein the capsule component comprises a gelled pharmaceutical capsule material and at least one surface, wherein the at least one surface comprises at least one integral feature with a lateral dimension smaller... Agent: Foley And Lardner LLP Suite 500
20110014133 - Compositions and methods to treat asthma: The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.... Agent: Dann, Dorfman, Herrell & Skillman
20110014132 - Solid effervescent mixture for the oral absorption: The present invention is a solid effervescent mixture for oral absorption which comes in the following forms: tablets, pills, granules, chewing gum, and candy. The formulation and preparation methods of the solid effervescent mixture are also disclosed. The solid effervescent formulation is administrated orally without water for dissolving and swallowing.... Agent: ProgressiveIPSolutions
20110014134 - Suspension aerosol formulations of pharmaceutical products: Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20110014135 - Vitamin formulation: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the... Agent: Glaxo Smith Kline C/o The Nath Law Group
20110014136 - Oral care product and methods of use and manufacture thereof: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with a soluble calcium salt, and to methods of using and of making such compositions.... Agent: Colgate-palmolive Company
20110014138 - Cosmetic water-in-oil emulsion compositions: Cosmetic water-in-oil emulsion compositions containing solid particles and high concentrations of a specific silicone elastomer and including high content of polysilicon-11, solid particles providing at least one optical effect, and at least one silicon emulsifier are suitable for use for making up the face and/or lips or eyelids, preferably as... Agent: Young & Thompson
20110014137 - Methods for protecting the skin from radiation insults: The present invention relates to methods and compositions for the protection of skin and mucous membranes from undesirable side effects of ionizing radiation in a patient undergoing ionizing radiation therapy. In particular, the application describes compositions and methods comprising the topical use of Nrf2 inducers.... Agent: Edwards Angell Palmer & Dodge LLP
20110014139 - Sun protection compositions: The invention relates to sun protection compositions for applying to the skin, containing special polyurethanes and to the use of the above-mentioned polyurethanes for producing sun-protection products.... Agent: Connolly Bove Lodge & Hutz, LLP
20110014140 - Process for the manufacture of substituted 2-cyano cinnamic esters: The invention relates to an improved process for the manufacture of substitute 2-cyanocinnamic esters. This novel economical process provides products in high purity and yields.... Agent: Nixon & Vanderhye, PC
20110014141 - Topical agent for dermatological use: The objective of the present invention was to enhance the skin whitening effects and blackening prevention effects and supply safe and stable topical agents for dermatological use. For that purpose 4-Hydroxyphenyl-α-D-glucopyranoside was combined with auxiliary agents such as ascorbic acid and its derivatives, crude drugs and its extracts, hydroxycarboxylic acid... Agent: Hoffmann & Baron, LLP
20110014142 - Cyclohexylethyl carboxylic acid ester compositions and method for using the same for reducing malodors: The present invention pertains to a method of counteracting a malodor by introducing a malodor counteracting effective amount of an enantiomeric compound selected from the group consisting of (1R)-1-cyclohexylethyl butyrate and (1S)-1-cyclohexylethyl acetate.... Agent: International Flavors & Fragrances Inc.
20110014143 - Ketones as perfuming ingredients: The present invention relates to the field of perfumery and concerns the use as perfuming ingredient of ketones of formula wherein n represents 0, 1 or 2, m represents 0, 1 or 2, the dotted lines represent only single bonds or one double bond and two single bonds, R1 represents... Agent: Winston & Strawn LLP Patent Department
20110014144 - Antiperspirant compositions: An antiperspirant composition comprising a mixing product of at least one salt chosen from at least one aluminum salt, at least one aluminum-zirconium salt, at least one aluminum salt complex, and at least one aluminum-zirconium salt complex; at least one cosmetically acceptable hydroxy acid; and at least one cosmetically acceptable... Agent: Colgate-palmolive Company
20110014145 - Hair conditioning composition: Provided is a low odor hair conditioning composition which is free of oily and greasy feel upon finish, and can impart good manageability and moisturized feel. Specifically provided is a hair conditioning composition including a component (A): a compound represented by a general formula (1) R1O—(PO)n/(EO)m—R2 (1), where R1 represents... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110014146 - Personal care fixative: The present invention is directed to bimodal polymer compositions and personal care fixatives containing bimodal polymer compositions. The present invention includes a bimodal polymer composition having a first polymer with anionic character and a second polymer with cationic character and wherein the polymers form an interpenetrating polymer network. In one... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20110014147 - Water-soluble resin, hair cosmetic material containing the same, and silicone oil adsorption assistant: Provided is a water-soluble resin which gives a conditioning effect when it is used in a hair cosmetic material containing an anionic surfactant, or the like. A water-soluble resin having a structure corresponding to a copolymer of a monomer mixture containing a vinylic monomer (A) having a hydroxyl group and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110014148 - Cationic surfactants having improved properties: The invention is directed to cationic surfactants of formula (I), where R1 is a saturated or unsaturated, branched or linear alkyl group having 6 to 22 carbon atoms, R2 and R3 independently are C1-C3 alkyl groups or hydrogen, n is 2 or 3, and X− is an anion selected from... Agent: Fox Rothschild LLP
20110014149 - Composition for skin external application containing complex of herbal extracts: Disclosed is a combination for skin external use, which contains as an active ingredient an herbal extract complex consisting of Chinese herbal extracts of Granate bark, seed of Prunus armeniaca, Coix lacuma-jobi, Saururus chinensis and Perilla frutescens var. aceta. More particularly, disclosed is a composition for skin external use containing... Agent: Nixon & Vanderhye, PC
20110014150 - Cosmetic method for smoothing wrinkles and fine lines: A cosmetic method for smoothing wrinkles and fine lines by a tightening effect, includes the application to the skin of a composition in the form of a water-in-oil emulsion containing, in a physiologically acceptable medium, an interpolymer including at least one polyurethane and at least one copolymer of vinylpyrrolidone and... Agent: Young & Thompson
20110014151 - Macromolecule conjugate: The invention relates to a macromolecule comprising a polymer central core having at least two atoms to which at least two monomers are attached forming a dendrimeric structure comprising at least three polymer bonds, at least two linear polymers (b) being bond to said polymer bonds, wherein said polymers (b)... Agent: Merchant & Gould PC
20110014152 - Increased t-cell tumor infiltration and eradication of metastases by mutant light: Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.... Agent: Barnes & Thornburg LLP
20110014153 - Reinforced tissue graft: A biocompatible tissue graft is provided. The tissue graft includes an extracellular matrix patch and a means for reinforcing the patch.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.
20110014154 - Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors: The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company
20110014155 - Reovirus for the treatment of cellular proliferative disorders: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the... Agent: Mckeon Meunier Carlin & Curfman LLC
20110014165 - Thymidylate kinase mutants and uses thereof: The invention relates to a composition comprising a stably integrating delivery vector; and a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk. The invention also relates to use of these compositions in methods... Agent: Ballard Spahr LLP
20110014156 - Bifidobacterium for dust mite allergy: A composition comprising Bifidobacterium breve for use in improving lung function in human subjects suffering from dust mite allergy.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20110014168 - Lactic acid bacteria having action of lowering blood uric acid level: Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high... Agent: Cooley LLP Attn: Patent Group
20110014166 - Probiotics spore-forming lactic acid bacteria sl153: The present invention relates to the novel Sporolactobacillus vineae SL153 strain (Accession No: KCTC 11493BP) having probiotic activity, precisely Sporolactobacillus vineae SL153 having antimicrobial activity against Vibrio genus pathogenic microorganisms and other pathogens. The Sporolactobacillus vineae SL153 strain of the present invention has excellent intestinal adherence and growth inhibitory effect... Agent: Greenlee Sullivan P.C.
20110014167 - Use of probiotics and fibers for diarrhoea: The present invention relates to nutritional compositions comprising Lactobacillus rhamnosus, inulin and soy polysaccharides for the treatment of diarrhoea.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20110014157 - Method for producing a mixture of bacteriophages and the use thereof in the therapy of antibiotic-resistant staphylococci: The invention relates to a method for producing a mixture of bacteriophages, wherein at least two different bacteriophage strains have been reproduced separately, wherein a staphylococcus strain is grown in an preculture with each of strains of a bacteriophage that can lyse staphylococci and is then further reproduced in a... Agent: Smith Patent Consulting, LLC
20110014161 - Cardiac tissue-derived cells: The present invention is directed to methods and compositions for repairing damaged myocardium using human cardiac tissue-derived cells. In particular, the present invention provides methods and compositions for repairing damaged myocardium using expanded human cardiac tissue-derived cells that do not express telomerase.... Agent: Philip S. Johnson Johnson & Johnson
20110014158 - Compositions and methods of using chondroitinase abci mutants: The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.... Agent: Pepper Hamilton LLP
20110014160 - Ddr1-mediated cell purification of pancreatic endocrine cells through their progenitors: The invention relates to a method of identifying, obtaining and/or quantifying a culture of pancreatic cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells. Also contemplated is a method of expanding the numbers of such cells as well... Agent: Novo Nordisk, Inc. Intellectual Property Department
20110014163 - Differentiation of human embryonic stem cells: The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.... Agent: Philip S. Johnson Johnson & Johnson
20110014164 - Efficient induction of pluripotent stem cells using small molecule compounds: The disclosure features a method of producing an induced pluripotent stem cell a somatic cell. The method includes contacting a somatic cell with a DNA methyl transferase inhibitor or a histone deacetylase (HDAC) inhibitor, or a combination thereof, to produce a pluripotent stem cell.... Agent: David S. Resnick
20110014159 - Method for obtaining characterized muscle-derived cell populations and uses: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of... Agent: Hunton & Williams LLP Intellectual Property Department
20110014162 - Preserved compositions of activated nk cells and methods of using the same: Disclosed herein are activated NK cells that exhibit durable and prolonged activity in the absence of the activating agent and retain their activated state after preservation. Methods of administrating the NK cells to a patient do not require co-administration of the activating agent, and thus, pharmaceutical compositions comprising the NK... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.
20110014169 - High affinity ny-eso t cell receptors: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to... Agent: Banner & Witcoff, Ltd.
20110014171 - Formulation and method for the prevention and treatment of bone metastases or other bone diseases: The invention relates to a suspension of erythrocytes encapsulating a bisphosphonate, for use as a medicament for the prevention and treatment of bone metastases and other bone marrow diseases. It also relates to a suspension of erythrocytes encapsulating a bisphosphonate, in which these erythrocytes have undergone a chemical treatment with... Agent: Stites & Harbison PLLC
20110014170 - Novel alpha-galactosidases: This invention relates to novel α-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of α3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the Galili... Agent: Foley & Lardner LLP
20110014172 - Recombinant human cln2 protein and methods of its production and use: The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2... Agent: Jones Day
20110014173 - Axl tyrosine kinase inhibitors and methods of making and using the same: Disclosed are novel inhibitors of the AxI receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy.... Agent: Sheridan Ross PC
20110014176 - Compounds and method for reducing uric acid: This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.... Agent: Wellstat Management Company. LLC
20110014174 - Lysozyme, a novel vasodilator of sepsis that can be inhibited by a peroxidase and hydroxyl radical scavengers: A method of reducing a vasodilatory response comprising administering to an individual in need of such treatment an effective amount of a guanylate cyclase pathway inhibitor selected from the group consisting of methylene blue, ODQ, LY83583 and a protein kinase G inhibitor or an H2O2 reducing agent selected from the... Agent: Ade & Company Inc.
20110014177 - Methods for enhancing physical and mental energy: A composition that includes thiamine disulfide diisobutyrate and caffeine. Related methods also are provided.... Agent: Don D. Cha
20110014178 - Antimicrobial composition and method for use: An antimicrobial composition and a method for administering the antimicrobial composition through the water or feed of livestock, wherein the antimicrobial composition is made up of lysozyme and various other agents that act synergistically with lysozyme, such as, dried egg powder, albumen, a sequestering agent and/or a lantibiotic. The composition... Agent: Beck And Tysver P.l.l.c.
20110014179 - Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) in a selected subpopulation of ich patients: The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age≦70, baseline ICH volume≦60 mL, baseline IVH volume≦5 mL, and elapsed time since onset of... Agent: Novo Nordisk, Inc. Intellectual Property Department
20110014182 - Antigen binding proteins: Antigen binding proteins that bind β-amyloid peptide, in particular human β-amyloid peptide; methods of treating diseases or disorders characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterised by elevated β-amyloid levels or β-amyloid deposits, including age related... Agent: Glaxosmithkline Global Patents -us, Uw2220
20110014186 - Arylsulfonamide-based matrix metalloprotease inhibitors: said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used... Agent: Novartis Institutes For Biomedical Research, Inc.
20110014184 - Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions: Whole organisms are inactivated by at least a factor of 106 using carbon dioxide at or near its supercritical pressure and temperature conditions.... Agent: Welsh Flaxman & Gitler LLC
20110014183 - Mcam modulation and uses thereof: Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM)... Agent: Goudreau Gage Dubuc
20110014185 - Methods involving graf polypeptides: t
20110014181 - Microneedle delivery device and methods of using same: Described herein are microneedle bioactive agent delivery systems, associated apparatus and methods of using such. The microneedles described herein are deliverable using a needle or syringe apparatus that can interface with existing medical devices or the devices can be used as standalone systems. The systems deliver at least one bioactive... Agent: Medtronic Vascular, Inc.IPLegal Department
20110014180 - Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restorati: A preparation containing atrial diuretic hormone family molecules are used for restoration and regeneration of a tissue and an organ. The preparation is used for growing hairs and/or for improving and restoring failures of skin, mucosa, and subcutaneous tissue such as bed bore, rough and dry skin, burn injuries, necrosis,... Agent: Flynn Thiel Boutell & Tanis, P.C.
20110014187 - Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes: Monoclonal antibodies directed against the influenza A virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza A virus. One preferred embodiment is the antibody designated as Fab28, which displays a neutralizing activity against a plurality of subtypes... Agent: Steinfl & Bruno
20110014191 - Breast cancer expression profiling: The present invention relates to a method for analyzing cancer. e.g., breast cancer including detection of differential expression of at least one of the 16 genes encoding serine/threonine kinases listed in Table 1, or of the 16 genes, and to a polynucleotide library including at least one the 16 genes.... Agent: Young & Thompson
20110014193 - Humanized anti-human alpha 9-integrin antibody: The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110014194 - Methods for inhibiting angiogenesis using egfl8 antagonists: The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.... Agent: Genentech, Inc.
20110014189 - Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents: A stable pharmaceutical composition with at least one monoclonal antibody and at least one amphiphilic polysaccharide chosen from the group of amphiphilic polysaccharides comprising carboxylate functional groups partly substituted with at least one hydrophobic substituent is disclosed.... Agent: Oliff & Berridge, PLC
20110014192 - Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators: Disclosed is a composition comprising a derivative of NDGA and at least one metabolic modulator. The composition can be in a unit dose form or kit. The composition can comprise at least two metabolic modulators. Also disclosed are methods for achieving cytotoxicity, particularly of rapidly dividing cells such as cancer,... Agent: Venable LLP
20110014188 - Tnfalpha antagonists and methotrexate in the treatment of tnf-mediated disease: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.... Agent: Cooper & Dunham, LLP
20110014190 - Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance: The invention relates to methods of preventing, treating, ameliorating and otherwise inhibiting organ or transplant rejection in a patient by administering B Lymphocyte Stimulator antagonists. In addition, therapeutic treatment regimens are provided to promote transplant tolerance in a patient following the administration of B Lymphocyte Stimulatorantagonists.... Agent: Leydig, Voit & Mayer Ltd.
20110014195 - Use of therapeutic peptides for the treatment and prevention of cancer: MUC1 (DF3, CD227, episialin, PEM) is a heavily O-glycosylated heterodimeric protein of >300 kDa, normally expressed abundantly on the apical surface of glandular epithelia. MUC1 mimetic peptides are selectively retained in mammary gland tumors, colon and skin after systemic administration. Moreover, MUC1 mimetic peptides reduce tumor initiation. In addition, MUC1... Agent: Banner & Witcoff, Ltd.
20110014196 - Drug transfer into living cells: The invention relates to compounds comprising a plurality of enzyme substrates suitably linked and further carrying one or more cargo entities. In particular such compounds have the structure (substrate)n-linker-(cargo)m wherein “substrate” is a substrate specific for an enzyme-type protein; n is 2 or more; “linker” is a linking unit consisting... Agent: Harriet M. Strimpel, D. Phil.
20110014197 - Methods of treating pre-eclampsia or eclampsia: Disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1—are also disclosed herein for the treatment of pre-eclampsia or eclampsia.... Agent: Clark & Elbing LLP
20110014198 - Anti-vegf antibodies: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in... Agent: Clark & Elbing LLP
20110014201 - Il-18 receptor antigen binding proteins: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.... Agent: Amgen Inc. Law Department
20110014202 - Methods for diagnosing and treating neuroendocrine cancer: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.... Agent: Licata & Tyrrell P.C.
20110014200 - Monoclonal antibody that suppresses thyrotropin receptor constitutive activity: This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancer... Agent: Davis Wright Tremaine LLP/los Angeles
20110014199 - Novel anti-il 13 antibodies and uses thereof: The present invention relates to anti IL13 antibodies that hind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies... Agent: Nikolaos C. George Jones Day
20110014203 - Formulation: A stable, aqueous pharmaceutical composition comprising an antibody having a heavy chain amino acid sequence of SEQ ID No: 3 and a light chain amino acid sequence of SEQ ID No: 4 and a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient, wherein said composition has a pH of 4 to 6.... Agent: Fish & Richardson P.C. (tc)
20110014204 - Cancer chemoprevention strategy based on loss of imprinting of igf2: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying... Agent: Dla Piper LLP (us)
20110014205 - Methods and compositions for treating chronic pelvic pain syndrome: The present invention provides methods and compositions for treating chronic pelvic pain syndrome. In particular, the present invention provides methods and compositions for treating chronic pelvic pain syndrome with an agent that targets MCP-1, MIP-1α, or the CCR-2 receptor.... Agent: Casimir Jones, S.c.
20110014206 - Screening method for predicting susceptibility to breast cancer: A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc)... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP
20110014207 - Combination treatment for non-hematologic malignancies: The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of... Agent: Pfizer Inc Mary J Hosley
20110014208 - Method of treating osteoarthritis with an antibody to ngf: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.... Agent: Regeneron Pharmaceuticals, Inc
20110014209 - Recombinant hcv e2 glycoprotein: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention... Agent: Foley And Lardner LLP Suite 500
20110014210 - Chlamydia vaccine: Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP
20110014211 - Composition for neutralizing botulinus toxin type-a, and human anti-botulinus toxin type-a antibody: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination... Agent: Edwards Angell Palmer & Dodge LLP
20110014212 - Certain chemical entities, compositions and methods: Provided is a method of treating myasthenia gravis in a patient by administering to the patient an effective amount of a skeletal muscle troponin activator, or a pharmaceutically acceptable salt thereof.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110014213 - Human anti-alpha 9 integrin antibody: The present invention provides a human anti-α9 integrin antibody or an antibody fragment which specifically recognize human α9 integrin and mouse α9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse α9 integrins, a gene encoding the antibody or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110014214 - Diagnostic and therapeutic utility of tribbles-2 in human cancers: Provided are methods for the diagnosis and treatment of acute myelogenous leukemia. In particular, the present invention relates to the use of Trib2 polynucleotides and polypeptides for the diagnosis and treatment of acute myelogenous leukemia (AML) by assessing myeloid cells of a patient, or malignancies associated with Trib2, C/EBPαp30 or... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP
20110014215 - Granulysin and uses thereof: Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP
20110014216 - Drug transfer based on coenzyme a and acyl carrier protein: The invention relates to coenzyme A (CoA) type compounds carrying one or more drug entities and optionally a label detectable by a fluorescence detector, magnetic resonance imaging (MRI), positron emission tomography (PET) or scintigraphy, and/or a functional group which can be transformed into a drug or a detectable label. The... Agent: Harriet M. Strimpel, D. Phil.
20110014217 - Carbon nanotube compositions and methods of use thereof: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T... Agent: Pabst Patent Group LLP
20110014218 - Ixodes scapularis salivary proteins and methods of use for modulation of the alternative complement pathway: Ixodes Scapularis salivary proteins, including Ixodes Scapularis anti-complement protein (Isac) and Isac-like protein family (ILP family) proteins, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. ILP family proteins, gene products and polypeptide fragments bind to proteins with thrombospondin repeats. Thus, therapeutic methods involving... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.
20110014221 - Hiv combination vaccine and prime boost: Provided is a novel, combination prime-boost vaccine against HIV/AIDS that induces long-lasting humoral, cell-mediated and mucosal immune responses against HIV.... Agent: Eduardo Krupnik
20110014220 - Human respiratory syncytial virus (rsv) vaccine: The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention... Agent: Occhiuti Rohlicek & Tsao, LLP
20110014219 - Norovirus and sapovirus antigens: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods... Agent: Novartis Vaccines And Diagnostics Inc.
20110014222 - Stereoisomer peptides and their polymer conjugates for hiv disease: The invention relates to a library of 298 peptides useful for formulating a novel therapeutic HIV vaccine. The peptide sequences were selected on the basis of calibration of molecular structure properties of HIV-1 or host cell proteins. A mixture of D- and L-amino acids or all D-amino acids are used... Agent: Lucia Irene Gonzalez
20110014225 - Cross-reactive determinants and methods for their identification: Compositions and methods for determining immunologically cross-reactive molecules comprising a cross-reactive antigenic determinant are provided, in particular for determining proteins comprising cross-reactive antigenic determinants, in particular for determining proteins that are cross-reactive based on serological screens using sequential immunological challenges to an animal, including determining cross-reactive H. parasuis proteins. Also... Agent: Novartis Animal Health US Inc.
20110014224 - Methods for producing an immune response to tuberculosis: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of... Agent: Klarquist Sparkman, LLP
20110014223 - Multimeric proteins able to induce an antibody response against the beta-amyloid and use thereof: The present invention relates to the fields of molecular biology, immunology and medicine. Peptide sequences that belong to the beta amyloid peptide are exposed on the surface of a multimeric structure derived from the E2 component of alpha keto acid dehydrogenase. The molecules are useful for the production of vaccines... Agent: Lucas & Mercanti, LLP
20110014226 - high throughput protein interaction assay: A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is... Agent: Merck
20110014228 - Il23 modified viral vector for recombinant vaccines and tumor treatment: The present invention relates to recombinant replicable viral vectors and viruses which are modified with IL23. This IL23 modified virus is highly immunogenic and attenuated for neurotropic pathology found in the wild type viruses. These viruses and vectors can be used for treatment of a variety of cancers and for... Agent: Nixon Peabody LLP - Patent Group
20110014227 - Pre-or post-exposure treatment for filovirus or arenavirus infection: The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two ore more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome).... Agent: Clark & Elbing LLP
20110014229 - Chimeric flavivirus vectors: The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors.... Agent: Clark & Elbing LLP
20110014230 - preparation of influenza virus vaccine antigens: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.... Agent: Novartis Vaccines And Diagnostics Inc.
20110014231 - Anti-measles cancer immunotherapy: The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20110014232 - Chimeric foot and mouth disease viruses: Foot and mouth disease (FMD) viruses which are able to grow on BHK-21 cells in suspension are described herein. The new viruses are recombinant chimeric viruses formed by replacing the outer capsid coding region of a first FMDV strain, which has previously been shown to be an effective vaccine strain,... Agent: Clark & Elbing LLP
20110014233 - Psoralen-inactivated viral vaccine and method of preparation: A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics.... Agent: Naval Medical Research Center Attn: (code 00l)
20110014234 - Monoparamunity inducers based on attenuated rabbit myxoma viruses: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and... Agent: Law Office Of Salvatore Arrigo
20110014236 - Novel protein capable of inhibiting anthrax toxin activity: The invention particularly relates to inhibition of the cleavage of protective antigen (PA) of Bacillus anthracis, which subsequently leads to inhibition of activity of anthrax toxin.... Agent: Birch Stewart Kolasch & Birch
20110014235 - Therapeutic and vaccine polyelectrolyte nanoparticle compositions: Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked... Agent: Perkins Coie LLP
20110014237 - Vaccine for protection against haemophilus parasuis serotype 4 in piglets: The present invention pertains to the use of Haemophilus parasuis serotype 5 bacteria in the manufacture of a vaccine for administration to a pregnant sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt after she has farrowed, against a disorder arising... Agent: Intervet/schering-plough Animal Health
20110014238 - Immunogenic protein pas n 1 from bahia grass pollen: The present invention relates generally to novel recombinant polypeptides of Bahia grass pollen and to genetic sequences encoding same. More particularly, the present invention is directed to Pas n 1 polypeptides and derivatives, and fragments thereof and genetic sequences encoding same. The molecules of the present invention are useful in... Agent: Knobbe Martens Olson & Bear LLP
20110014239 - Preparation of vaccines using photosensitizer and light: Methods are provided for treating a vaccine containing infectious particles which may be viral, bacterial, and/or cellular in nature. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid and exposing the fluid to photoradiation sufficient to inactivate the infectious particles but... Agent: Caridianbct, Inc. Mail Stop: 810 1f2
20110014240 - Single cycle replicating adenovirus vectors: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for... Agent: Fish & Richardson P.C. (tc)
20110014241 - Therapeutic cancer antigens: The present invention relates to cells, pharmaceutical compositions, tumor vaccines, kits and methods for inhibiting cell proliferation or tumor growth in a mammal, specifically, the invention relates to cells that express a tumor-associated tumor antigen.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20110014242 - Promoters for expression in modified vaccinia virus ankara: The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.... Agent: Law Office Of Salvatore Arrigo
20110014246 - Amorphous arformoterol l-(+)-tartrate: Disclosed herein is a novel and stable amorphous form of arformoterol L-(+)-tartrate, a process for its preparation, pharmaceutical compositions comprising amorphous arformoterol L-(+)-tartrate, and methods of treating with amorphous arformoterol L-(+)-tartrade.... Agent: Cantor Colburn LLP
20110014244 - Inorganic shaped bodies and methods for their production and use: Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A... Agent: Woodcock Washburn LLP
20110014247 - Methods and compositions for oral administration of proteins: This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.... Agent: Wolf Greenfield & Sacks, P.C.
20110014243 - Pharmaceutical compositions: Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with a basic filler. Such formulation acts to prevent the formation of undesired reaction products. The compositions may be formed into granules or a tablet which may optionally be enterically coated.... Agent: Wiggin And Dana LLP Attention: Patent Docketing
20110014245 - Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation: A titanium dioxide composite is provided that can be stably dispersed in an aqueous solvent and easily administered into a living body, such as human, and allows elimination of the drug efficacy of a pharmaceutical compound supported thereon by light irradiation and a dispersion thereof. A composite is used in... Agent: Carrier Blackman And Associates
20110014248 - Cosmetic use of microorganism(s) for the treatment of scalp disorders: The present invention relates to a use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic process for preventing and/or treating a dandruff condition including the administration... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110014250 - Inhibitors of 15-hydroxyprostaglandin dehydrogenase for stimulating pigmentation of the skin or skin appendages: Inhibitors of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), for example tetrazole, styrylpyrazole, phenylfuran, phenylthiophene, phenylpyrrazole, pyrazolecarboxamide, 2-thioacetamide and azo compounds, are useful for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for preventing and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, notably for preventing and/or limiting... Agent: Buchanan, Ingersoll & Rooney PC
20110014251 - Microvesicles: A method of producing a population of differentiated cells comprising: a) inducing differentiation in a first population of cells by applying an inducer to said cells, b) harvesting microvesicles produced from first population of cells, and c) inducing differentiation in a second population of cells by applying said microvesicles or... Agent: Mcandrews Held & Malloy, Ltd
20110014253 - Personal care implement containing a stable reactive skin care and cleansing composition: Skin care or cleansing implements are described containing a liquid, semi-solid or solid cleansing or skin treatment composition that is releasably associated with the implement. The composition is substantially nonaqueous and has a continuous and a discontinuous phase. Components of the discontinuous phase can react with each other or with... Agent: Unilever Patent Group
20110014252 - Tooth whitening products: A tooth whitening product is provided. The tooth whitening product has a backing layer and a tooth whitening composition. The tooth whitening composition includes first and second water soluble polymers, water, and a tooth whitening agent, wherein the first water soluble polymer is polyethelene oxide and the second water soluble... Agent: The Procter & Gamble Company Global Legal Department - Ip
20110014249 - Two-part cosmetic product with volumizing effect to hair fibers: The present invention relates to a two-part cosmetic product that imparts a filling and/or swelling effect to hair, eyebrows or eyelashes, preferably a mascara. The invention uses an anhydrous base coat composition with a water absorbing ingredient being a salt of acrylic or polyacrylic acid and a CO2 releasing compound... Agent: Gregory A. Nelson Novak Druce & Quigg LLP
20110014254 - Uv-blocking cosmetics prepared by being impregnated with urethane foam: The present invention relates to a cosmetic product comprising a UV-blocking W/O or O/W composition of low viscosity packaged in a compact-type container. More specifically, the invention relates to a UV-blocking cosmetic product prepared by impregnating a UV-blocking W/O or O/W cosmetic composition of low viscosity into expanded urethane foam,... Agent: Nixon & Vanderhye, PC
20110014256 - Long-lasting anti-microbial composition and anti-microbial film and spray thereof: A long-lasting anti-microbial composition is provided, which includes one or more polymer or oligomer and a plurality of nanowires distributed therein, wherein the nanowires have an aspect ratio of more than 20 and the nanowires form a network-like structure. An anti-microbial film and spray including the composition are also provided.... Agent: Birch Stewart Kolasch & Birch
20110014255 - Phytosanitary formulation generating nanoparticles, method for preparing nanoparticles and use thereof: The present invention relates to a phytosanitary formulation capable of generating nanoparticles. The formulation includes a solvent having a low water miscibility, an active ingredient and at least one amphiphilic compound. The formulation is concentrated and is intended to be diluted in water by a farmer. The present invention also... Agent: Hunton & Williams LLP Intellectual Property Department
20110014257 - Biodegreadable device with slow-release of volatile products having an attractant action for the control of insects: The invention describes a biodegradable device with a slow-release of volatile products having an attractant action with respect to insects, which can be applied to a wide range of crops.... Agent: Hedman & Costigan, P.C.
20110014258 - Gradient coating for biomedical applications: The present invention provides a coating comprising a bioactive material and an antimicrobial agent, wherein the concentration of said antimicrobial agent varies throughout the thickness of the coating.... Agent: Diana Houston Smith & Nephew, Inc.
20110014259 - Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis: Effective treatments of hematomas, edema, or other fluid accumulation or deep vein thromboses are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat edema, or other fluid accumulation or deep vein thromboses.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department
20110014260 - System and method for liver cell culture and maturation: The present invention relates to systems and methods for maturation, proliferation and maintenance of function in cells presenting hepatocyte characteristics and differentiated from stem cells. The cells of the present invention may be generated from stem cell grown in collagen sandwich configuration in the presence of a morphogen (e.g. S-NitrosoAcetylPenicillamine... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20110014262 - Controlling vessel growth and directionality in mammals and implantable material: A method for directing vessel growth toward a blood-deficient site in a mammal comprising implanting into the mammal an assembly of at glass fibers to form a vascular bridge with a first end of the vascular bridge in contact with the blood-deficient site and a second end of the vascular... Agent: Senniger Powers LLP
20110014266 - Expandable, porous apatite/collagen composite, and its production method: A expandable porous body constituted by a compressed apatite/collagen composite, which expands by water absorption, and a method for producing an expandable, porous apatite/collagen composite, which expands by water absorption, comprising the steps of freezing a porous apatite/collagen composite impregnated with a liquid in a compressed state, and drying it.... Agent: Greenblum & Bernstein, P.L.C
20110014265 - Implant improving local bone formation: A bone implant comprises an active agent on at least a portion thereof. The active agent is locally deliverable to bone proximate the implant in at least a two-phased release scheme. A first phase rapidly releases a first quantity of the active agent, and at least a second phase gradually... Agent: Mccarter & English, LLP Stamford
20110014264 - Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery: According to certain aspects of the invention, implantable or insertable medical devices are provided that contain one or more nanoporous regions, which may further comprise interconnected nanopores. Other aspects of the invention are directed to implantable or insertable medical devices that contain one or more nanostructured regions, which are formed... Agent: Fish & Richardson P.C. (bo)
20110014261 - Scaffold for tissue regeneration in mammals: A three-dimensional scaffold with interconnected pores for repair of tissue comprising a scaffold body for structural support of the tissue scaffold, where the scaffold body comprises scaffold body components bonded to each other and made from component materials comprising about 40 to about 90 wt % B2O3, and two or... Agent: Senniger Powers LLP
20110014263 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.
20110014267 - Biosynthetic cartilaginous matrix and methods for their production: An isolated, acellular biosynthetic cartilaginous matrix substantially devoid of synthetic biodegradable scaffold structure is provided. Through a method with the steps of a) contacting in vitro a population of chondrogenic cells with a synthetic biodegradable scaffold; b) culturing in vitro for a period of time said chondrogenic cells within said... Agent: Jacobson Holman PLLC
20110014268 - Formulation for oral administration: a drug storing portion (12a) which is adjacent to the liquid storing portion (11) and in which peripheries of overlaid edible films (10) are bonded and a closed space is formed inside the films and a drug (Da) is stored inside the space.... Agent: Apex Juris, PLLC
20110014269 - Civamide patch for localized post-incisional neuropathic pain: A dermal method of treating chronic post-operative pain with a TRPV-1 receptor modulator. More specifically, a method for treating localized post-incisional neuropathic pain by administering a civamide-containing patch.... Agent: Barnes & Thornburg LLP
20110014275 - Compositions and methods for inhibiting or inducing adipogenesis: This invention relates generally to compositions and methods which utilization nuclear receptors for regulating adipogenesis in cells. Specifically, the invention is directed to compositions which regulate transcription factor PPARγ, and enhance or inhibit the transcription of genes responsible for directing cell differentiation towards a pathway of adipogenesis. More specifically, disclosed... Agent: The Law Office Of Randolph Bretton
20110014272 - Method for adjuvanting lipopolysaccharide (lps) of gram-negative bacteria: The subject of the invention is a method for adjuvanting LPS of a Gram-negative bacterium, according to which LPS or LPS liposomes (LPS formulated in liposomes) is (are) mixed with the lipidated human-transferrin receptor subunit B (TbpB protein) of Neisseria meningitidis or a lipidated fragment thereof; or (ii) LPS and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20110014273 - Method of treating bcc: A method of treating chronic infection with B. cepacia complex (BCC) in a patient suffering from cystic fibrosis (CF) comprising administering a fluidosomal formulation of tobramycin to the patient.... Agent: Loza & Loza LLP
20110014270 - Prevention and treatment of ischemia-reperfusion injury and related conditions: Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and/or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion... Agent: Sheridan Ross PC
20110014277 - Smoking cessation with body weight maintenance and nutritional supplement: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting... Agent: Klaas, Law, O''meara & Malkin, P.C.
20110014271 - Substituted aniline derivatives: The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.... Agent: Wilson, Sonsini, Goodrich & Rosati
20110014276 - Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide: An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range... Agent: Stetina Brunda Garred & Brucker
20110014274 - Vaccine composition containing synthetic adjuvant: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from... Agent: Seed Intellectual Property Law Group PLLC
20110014279 - Bioactive complex compositions and methods of use thereof: A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, Omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein... Agent: Rosenbaum & Silvert, P.C.
20110014278 - Compositions comprising dehydrated micro-organisms, method for preparing same, and uses thereof: The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 μm. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products.... Agent: Westerman, Hattori, Daniels & Adrian, LLP
20110014281 - Drug delivery system for administration of poorly water soluble pharmaceutically active substances: This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size... Agent: Renner Otto Boisselle & Sklar, LLP
20110014282 - Pharmaceutical composition for poorly soluble drugs: A pharmaceutical composition containing a solid dispersion of a poorly soluble active pharmaceutical ingredient, an amorphous carrier and a surfactant.... Agent: Foley & Lardner LLP
20110014280 - Sequestering subunit and related compositions and methods: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein,... Agent: Patrick J. Halloran, Ph.d., J.d
20110014283 - Novel dosage form: The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Global Patents
20110014284 - Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof: The present invention relates to pharmaceutical compositions comprising a SGLT-2 inhibitor, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation
20110014285 - N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen: The present invention relates to compositions for improving the efficacy of acetaminophen comprising a unit dose of acetaminophen and a therapeutic efficacy-enhancing amount of N-acetylcysteine, such that acetaminophen and N-acetylcysteine are present in the composition in a molar ratio of acetaminophen to N-acetyl cysteine ranging from about 1:15 to about... Agent: Greenberg Traurig, LLP
20110014286 - Mixture for producing rapidly disintegrating tablets: An isomalt-containing mixture including a) 60-97% by weight of agglomerated isomalt, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 0.1-15% by weight of lubricant, d) 1-15% by weight of water-insoluble, film-forming polymers, e) 0-15% by weight of water-soluble polymers and f) 0-15% by weight of pharmaceutical auxiliaries, where the sum... Agent: Ostrolenk Faber Gerb & Soffen
20110014288 - Microcapsules comprising a fat-soluble active substance:
20110014287 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.
20110014289 - Reticulated elastomeric matrices, their manufacture and use in implantable devices: This invention relates to biodurable, reticulated elastomeric matrices that are resiliently-compressible, their manufacture and uses including uses for implantable devices into or for topical treatment of patients, such as humans and other animals, for therapeutic, nutritional, or other useful purposes.... Agent: King & Spalding
20110014290 - System and method for facilitating hemostasis with an absorbable sponge: The present invention provides for a method and apparatus to provide hemostasis at a blood vessel puncture site, having a hemostasis material and a clot formation accelerator, wherein said clot formation accelerator is substantially dispersed throughout said hemostasis material.... Agent: Seager, Tufte & Wickhem, LLC
20110014292 - method of prophylaxis and agents for use therein: The present invention relates generally to a method of prophylactically or therapeutically treating antigen-induced airway tissue inflammation and agents for use therein. More particularly, the present invention provides a method of prophylactically or therapeutically treating allergic airway inflammation and agents for use therein via the administration of the method of... Agent: Knobbe Martens Olson & Bear LLP
20110014293 - Cleavage kit, and gene therapy by using the same and nucleic acid cleavage detection apparatus: A nucleic acid cleavage kit is used to cleave a target nucleic acid. The nucleic acid cleavage kit includes a carrier, an oligonucleotide, and a nucleic acid cleavage agent. The oligonucleotide recognizes at least partial sequence of the target nucleic acid. Then, the nucleic acid cleavage agent cleaves the target... Agent: Muncy, Geissler, Olds & Lowe, PLLC
20110014291 - Novel polymorphs of bosentan: Disclosed herein are novel polymorphic forms of bosentan, processes for preparation, pharmaceutical compositions, and method of treating thereof.... Agent: Cantor Colburn LLP
20110014294 - Stimulation of ocular retrobulbar blood flow using ocular irritants: Disclosed are uses of an ocular irritant such as saponin in stimulating the retrobulbar blood flow of an eye. Disclosed are also methods of treatment including administration of a pharmaceutical composition including an ocular irritant to an eye, for example as a mist, in order to stimulate the retrobulbar blood... Agent: Fennemore Craig
20110014296 - Drug delivery nanodevice, its preparation method and uses thereof: Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP
20110014297 - Multimodal therapeutic hybrid particle complex and system: A multiple layer microbubble drug delivery system, multiple layer microbubble drug delivery vehicle, method thereof and fabrication method are disclosed. The microfluidic drug delivery system for producing multiple layer microbubbles includes a first inlet which receives a gas and directs the gas into a central stream, a second inlet which... Agent: Murabito, Hao & Barnes, LLP
20110014298 - Discontinuous surface coating for particles: The present invention relates to particle compositions comprising a core particle that is partially coated with a first hydrophilic deposit and a hydrophobic polymeric finish, contains a small amount of water, and a compatible active present in the deposit, the finish or both. Additional alternating deposits, hydrophobic, hydrophilic or both,... Agent: The Estee Lauder Cos, Inc
20110014299 - Solid preparation comprising alogliptin and metformin hydrochloride: The present invention provides a solid preparation containing compound (I) [compound (I) is as defined in the specification] or a salt thereof, and metformin hydrochloride, which is useful as a therapeutic drug for diabetes and the like, and superior in the preservation stability. A solid preparation having a first part... Agent: Foley And Lardner LLP Suite 500
20110014300 - Template free and polymer free metal, nanosponge and a process thereof: The present invention provides solution to the problem involved in preparation of metal nanosponges using templates and polymers. The instant invention is successful in providing a simple, template free single step process for the preparation of metal nanosponges having porous low density and high surface area. These metal nanosponges were... Agent: Harness, Dickey & Pierce, P.L.C
20110014301 - Metal compounds, mixed or sulphated, as phosphate binders: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably... Agent: Mayer Brown LLP
20110014303 - Method for the treatment of cancer: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic... Agent: David S. Resnick
20110014302 - Use of transplatin to prevent hearing loss: Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and... Agent: Polsinelli Shughart PC
20110014304 - Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders: The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders,... Agent: Dechert LLP
20110014305 - Extracts of eleutherococcus spp., preparation method thereof and use of the same: The present invention relates to extracts of Eleutherococcus spp. and the preparation process thereof. The present invention also relates to the use of the Eleutherococcus spp. extracts of the present invention for the treatment or prevention of at least one condition of metabolic syndrome.... Agent: Olson & Cepuritis, Ltd.
20110014306 - Formulations with sanguinarine, chelerythrine or chelidonine for the treatment of warts, verrucas and psoriatic plaques: The invention provides formulations containing sanguinarine, chelerythrine or chelidonine or their salts or extracts containing them, mixed with suitable vehicles and/or excipients, for the treatment of common skin warts and verrucas, anal and vulvar warts and psoriatic plaques.... Agent: Lucas & Mercanti, LLP
20110014307 - Blood vessel maturation, normalization or stabilization agent and wrinkle preventer/improver: A vascular maturation, normalization or stabilization agent, or a Tie-2 activation agent, is provided comprising an extract derived from a plant belonging to the genus Cinnamomum.... Agent: Foley And Lardner LLP Suite 500
20110014309 - Composition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a method for its preparation: A method of producing a product to correct hypercholesterolemia including pulping fruits of Emblica officinalis with demineralized water to create a slurry. The slurry is treated with pectinase. The pectinase-treated slurry is filtered to create a solution. The solution is concentrated to create a product. A product having an extract... Agent: Jyoti C. Iyer
20110014308 - Novel compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders.: The present invention relates to novel compositions comprising hydroxytyrosol and chondroitin as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.... Agent: Nixon & Vanderhye, PC01/13/2011 > 229 patent applications in 114 patent subcategories. recently filed with US Patent Office
20110008248 - Peptide antagonists of tgf-beta family members and therapeutic uses thereof: This invention is drawn to methods of using peptide-based antagonists of TGF-beta to facilitate the healing of cutaneous wounds that includes burns, lacerations and scrapes. The administration of peptide TGF-beta antagonists to wounds results in reduced scarring, wound contraction and deposition of extracellular matrix components, and increased rates of reepithelialization... Agent: Elmore Patent Law Group, PC
20110008249 - Proteins with high immunoreactivity and method for their production: The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies... Agent: Ursula B. Day Ursula B. Day, Esq.
20110008250 - Treatment of autoimmune diseases: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.... Agent: Sidley Austin LLP
20110008251 - Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as... Agent: Immunomedics, Inc.
20110008252 - Stabalised 99mtc compositions: The present invention relates to stabilised 99mTc radiopharmaceutical compositions of the ligand tetrofosmin, which include an ascorbic acid or ascorbate radioprotectant, in the absence of an antimicrobial preservative. The invention also provides lyophilised kits suitable for the bulk preparation of multiple unit patient doses of 99mTc-tetrofosmin metal complexes. Also disclosed... Agent: Ge Healthcare, Inc.
20110008253 - Process for production of heterodimers of glutamic acid: e
20110008254 - Radiopharmaceutical composition: The present invention relates to radiopharmaceuticals and in particular to a radiopharmaceutical composition comprising a compound of Formula (I): and polysorbate as an excipient. The radiopharmaceutical composition of the invention reduces problems encountered with prior art compositions comprising the same class of compounds. Also provided by the invention is a... Agent: Ge Healthcare, Inc.
20110008255 - Beta-amyloid pet imaging agents: Novel derivatives of imidazopyridinylbenzeneamines and novel derivatives of benzothiazolylbenzeneamines are disclosed that offer improved behavior when used as imaging agents for positron emission tomography of beta-amyloids. Also disclosed is a palladium-catalyzed reaction scheme under microwave conditions for aryl thioethers in general that provides a high ratio of substitution relative to... Agent: Cantor Colburn LLP - National Institutes Of Health
20110008257 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati
20110008256 - Monoclonal antibodies that bind or neutralize dengue virus: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further... Agent: Ott-nih C/o Edwards Angell Palmer & Dodge LLP
20110008258 - Methods relating to breathing disorders: Methods for treating breathing disorders by inhibition of the induced PGE2 pathway in a mammalian subject, methods for assessing apnea, hypoxic ischemic encephalopathy or perinatal asphyxia by detecting an elevated level of PGE2, or a metabolite thereof, in a sample from the subject compared with a control level, and in... Agent: Birch Stewart Kolasch & Birch
20110008259 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.... Agent: Vertex Pharmaceuticals Inc.
20110008261 - Method to produce hyperpolarised amino acids and aminosulphonic acids: The invention relates to a dynamic nuclear polarisation (DNP) method for producing hyperpolarised amino acids and amino sulphonic acids and compositions for use in the method. As a sample, an ammonium salt of an amino acid, an ammonium salt of an aminosulphonic acid, a carboxylate salt of an amino acid,... Agent: Ge Healthcare, Inc.
20110008260 - Use of nanocrystals for drug delivery from a balloon: A drug delivery balloon (10) has a drug thereon in the form of crystalline particles (12), the drug having a predetermined size distribution. Optionally marker particles (14, 16) are also provided. A texturized coating (18), a cap layer (20) and/or other methods may be used to increase particle loading capacity... Agent: Vidas, Arrett & Steinkraus, P.A.
20110008263 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CO—CH3)—X—N(CO—CH3)—R and salts or optical active isomers thereof,... Agent: Ge Healthcare, Inc.
20110008262 - Drug delivery system targeting to estrogen receptor over-expressed cells: A vector for targeted delivery of drugs into estrogen receptors over-expressed cells is disclosed. The vector of the present invention is mainly about an active targeting delivery carrier which consists of a plurality of nanoparticles including: (i) a plurality of targeted moiety conjugated to the outer surface of the nanoparticles,... Agent: Birch Stewart Kolasch & Birch
20110008265 - In situ polymerization for hair treatment: Hair care products represent a world-wide multi-billion dollar industry. Pre-formed polymers are commonly used in a variety of hair care products including shampoos, conditioners, gels, and hair sprays. The present invention provides technology for polymerizing monomers on hair in situ to produce desired hair characteristics. This eliminates the solubility and... Agent: Fitzpatrick Cella Harper & Scinto
20110008267 - Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof: A method for treating a disease or disorder of the skin or scalp of a mammal while simultaneously cleansing the skin or scalp is disclosed. The method includes administering to the skin or scalp a mousse formed from a composition that includes a therapeutically or cosmeceutically effective amount of at... Agent: Thompson Hine L.L.P. Intellectual Property Group
20110008266 - Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses: Pharmaceutical or cosmetic compositions and methods for their use are provided comprising water and a surfactant polymer system comprising a Poloxamer at a concentration of about 0.1% to about 15% by weight; wherein when the Poloxamer is between about 0.1% to about 5% Poloxamer. The composition can further comprise a... Agent: Wilmerhale/boston
20110008269 - Compositions and methods which modulate g-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman
20110008268 - Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110008270 - Composition containing a water-miscible liquid and a water-soluble particle, method of production and use thereof: The invention relates to a water-soluble composition comprising a water miscible liquid and water-soluble particles, the water-soluble composition being essentially free of water. The composition can be used e.g. as dental composition, cleaning agent, polishing agent, tongue surface cleaning agent or peeling agent.... Agent: 3m Innovative Properties Company
20110008271 - Rosacea treatments using polymetal complexes: Described herein are novel methods for the treatment of rosacea which include the step of applying of a composition containing a polymetal complex to an area of the skin afflicted with rosacea and novel regimens using such compounds.... Agent: Carter, Deluca, Farrell & Schmidt, LLP
20110008272 - Use of creatine or creatine compounds for skin preservation: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary... Agent: Mccarter & English, LLP Boston
20110008273 - Methods of skin whitening and of screening skin-spot-formation inhibiting and/or skin-spot removing factor: A method of skin whitening is provided which includes: selectively activating proliferation and/or differentiation of melanin-containing keratinocytes of the skin.... Agent: Mcdermott Will & Emery LLP
20110008274 - Cosmetic composition comprising at least one fixing polymer and at least one amphoteric starch: A cosmetic composition for the treatment of keratinous fibres, in particular hair, comprising at least one fixing polymer and at least one amphoteric starch and the process for treatment of keratinous fibres using said composition.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110008275 - Methods of cleansing dyed hair: Provided are methods of cleansing dyed hair comprising applying to dyed hair a composition comprising anionic surfactant and a hydrophobically-modified polymer capable of binding surfactant thereto.... Agent: Philip S. Johnson Johnson & Johnson
20110008276 - Ethyleneoxide butyleneoxide block copolymer compositions: The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated.... Agent: Alcon
20110008277 - Polyol-based polymers: The present invention provides inventive polyol-based polymers, materials, pharmaceutical compositions, and methods of making and using the inventive polymers and materials. In certain aspects of the invention, an inventive polymer corresponds to a polymer depicted below. Exemplary inventive polymers includes those prepared using polyol units (e.g., xylitol, mannitol, sorbitol, or... Agent: Choate, Hall & Stewart LLP
20110008278 - Modulators of paraptosis and related methods: The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound. selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (RMPA), kainic acid and glutamic acid, wherein the... Agent: Morrison & Foerster LLP
20110008281 - Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia: The present invention provides methods, compositions, and systems for treating a subject at risk for, with, or suspected of having, myocardial ischemia using hepatocyte secretory factors (e.g., AGP2, BMPER, FGF21, NRG4, and/or TFF3) or using factors that promote liver cell migration to ischemic myocardial tissue (e.g., IL-6 and/or MMP-2).... Agent: Casimir Jones, S.c.
20110008282 - Il-1alpha immunization induces autoantibodies protective against atherosclerosis: Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease,... Agent: Xbiotech, Inc.
20110008279 - Methods and compositions relating to adhesins as adjuvants: This invention is in the field of immunology and relates to the discovery that adhesins are potent activators of dendritic cells.... Agent: Novartis Vaccines And Diagnostics Inc.
20110008280 - Methods for treating viral infection using il-28 and il-29 cysteine mutants: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department
20110008283 - Interferon fusion proteins: The disclosure relates to interferon fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers.... Agent: Klarquist Sparkman, LLP
20110008287 - Methods and means for the treatment of hpv induced intraepithelial neoplasias: The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the anogenital tract, such as HPV induced vulvar, cervical, vaginal, penile and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20110008284 - Novel clyclosporin analogues: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.... Agent: Elmore Patent Law Group, PC
20110008285 - Novel cyclosporin analogues: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.... Agent: Elmore Patent Law Group, PC
20110008286 - Novel proline substituted cyclosporin analogues: The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.... Agent: Elmore Patent Law Group, PC
20110008288 - Hepatitis c virus inhibitors: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC
20110008289 - Hyperglycosylated polypeptide variants and methods of use: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide... Agent: Knobbe Martens Olson & Bear LLP
20110008290 - Method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon: A method for predicting a response of a patient to a medical treatment with interferon, wherein the method includes detecting the allele identity of a polymorphism in the OAS1 gene in a nucleic acid sample previously obtained from the patient, and optionally detecting the allele identity... Agent: Young & Thompson
20110008302 - Compositions and methods for immortalizing cells and screening for anti-cancer agents: An embodiment of the invention provides methods and compositions for immortalizing cells, and in another embodiment for reversing immortalization of cells. Methods for screening for anti-cancer agents by identifying compounds that bind to and inhibit activity of an Ndy protein are also provided. Novel cancer diagnostic and prognostic methods using... Agent: Lawson & Weitzen, LLP
20110008292 - Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof: Fructooligosaccharide (FOS)-related protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, FOS-related fusion proteins, antigenic peptides, and anti-FOS-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and host cells into... Agent: Alston & Bird LLP
20110008291 - Use of antifungal compositions to treat upper gastrointestinal conditions: The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal... Agent: Klauber & Jackson
20110008303 - Methods for treatment and prevention of mrsa/mssa: Described herein are methods for treating and preventing MRSA/MSSA. The present subject matter deviates from current treatment methods by introducing a controlled decolonization/recolonization method, which eradicates the host surface area of MRSA/MSSA, and colonizes the newly cleared surface area with a nonpathogenic or pathogenic bacteria capable of out-competing MRSA/MSSA.... Agent: Davis Wright Tremaine LLP/los Angeles
20110008293 - Device and method for preparing microparticles: The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles.... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP
20110008294 - Methods for treating cancer with mva: The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.... Agent: Bn Immuno Therapeutics, Inc.
20110008295 - Simian adenoviruses sadv-36, -42.1, -42.2, and -44 and uses thereof: A recombinant vector comprises simian adenovirus 36, simian adenovirus 42.1, simian adenovirus 42.2 and/or simian adenovirus 44 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses one or more simian adenovirus-36, -42.1, -42.2 or -44 gene(s) is also described. Methods of using the... Agent: Howson & Howson LLP
20110008300 - Cryopreservation of adipose tissue for the isolation of mesenchymal stem cells: The present invention relates to a method and composition for the cryopreservation of adipose tissue with the intention to use this tissue in the culturing of stem and/or progenitor cells. The method uses a specific cryoprotection medium to prevent damage of the original tissue during the cryopreservation while still maintaining... Agent: Mcandrews Held & Malloy, Ltd
20110008301 - Human adipose derived insulin making mesenchymal stem cells for treating diabetes mellitus: The invention provides a novel therapeutic composition comprising of insulin producing mesenchymal stem cells obtained from human adipose tissue along with Hematopoietic stem cells for the treatment of diabetic patients especially insulinopenic patients. The invention also describes a simple and efficient process for the isolation, proliferation and differentiation of insulin... Agent: Davidson, Davidson & Kappel, LLC
20110008298 - Method of deriving progenitor cell line: We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to... Agent: Cohen & Grigsby, P.C.
20110008296 - Muscle-derived cells having differentiation capacities:
20110008297 - Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling: Synthetic oxysterols can be made and can be used for the treatment of bone disorders, obesity, cardiovascular disorders, and neurological disorders.... Agent: Venable LLP
20110008299 - Treatment of pelvic floor disorders with an adipose-derived cell composition: A method for treating a pelvic floor disease comprises removing adipose tissue from a patient, processing a first portion of the adipose tissue to obtain a heterogeneous mixture of cells that includes adipose-derived stem cells, combining the heterogeneous mixture of cells with a second, unprocessed portion of the adipose tissue... Agent: Ams Research Corporation
20110008304 - Use of cells to facilitate targeted delivery of nanoparticle therapies: The present invention is related to the use of cells, such as stem cells or immune system cells, to deliver nanogels comprising an active agent to a desired site in the body. The present invention utilizes cells as a delivery system for active agents that are difficult to deliver, such... Agent: Casimir Jones, S.c.
20110008307 - Cephalotaxine alkaloid compositions and uses thereof: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of... Agent: Morgan, Lewis & Bockius, LLP (sf)
20110008308 - Composition for hair, skin, nails: A pharmaceutical composition for use in hair, skin and nail health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists of a daily intake of 1 tablet that consists of: 5 mcg Vitamin D3, 40 mg Vitamin E... Agent: Robert Taylor Vitabiotics Limited
20110008306 - Creatine-ligand compounds and methods of use thereof: The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject.... Agent: Mccarter & English, LLP Boston
20110008305 - Nano-emulsion composition of coenzyme q10: The present invention provides a nano-emulsion composition of CoQ10 comprising 5 to 20 wt. % of CoQ10, 1 to 5 wt. % of ethanol, 1 to 5 wt. % of lecithin, 20 to 30 wt. % of caprylic/capric glyceride or vegetable oil(s), 10 to 20 wt. % of glycerin, 1... Agent: Patent Correspondence Arnall Golden Gregory LLP
20110008309 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent: K&l Gates LLP
20110008310 - Methods and compositions for mitochondrial replacement therapy: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.... Agent: Clark & Elbing LLP
20110008311 - Animal model and use of 17beta-hydroxysteroid dehydrogenase type 7 in the diagnosis of anencephaly: The present invention features a non-human animal in which is deficient in the expression of endogenous 17β Hydroxysteroid Dehydrogenases Type 7 and use of the same in screening methods for agents that prevent or treat anencephaly. The present invention also provides a method for diagnosing and treating.... Agent: Licata & Tyrrell P.C.
20110008312 - Radical therapeutic agent for keloid and hypertrophic scar: An effective therapeutic agent for keloids and/or hypertrophic scars is provided. Specifically, an elastic fiber regenerating agent consisting of chondroitinase ABC derived from Proteus vulgaris and a therapeutic agent for keloids and/or hypertrophic scars comprising the regenerating agent as an active ingredient are provided.... Agent: Knobbe Martens Olson & Bear LLP
20110008313 - Tpa mutant in the treatment of acute brain injury and neurodegenerative disorders: The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.
20110008314 - Methods of and compositions for inhibiting the proliferation of mammalian cells: A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.
20110008316 - Biological bioadhesive compositions and methods of preparation and use: The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the... Agent: O'keefe, Egan, Peterman & Enders LLP
20110008315 - Recombinant elastase proteins and methods of manufacturing and use thereof: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described... Agent: Dechert LLP
20110008317 - Charcoals: Non-activated charcoals from living plant materials are useful as ion exchange agents for adsorbing cations from an environment, especially metal ions.... Agent: Foley & Lardner LLP
20110008322 - Anti-c35 antibody combination therapies and methods: The present invention is directed to methods of killing cancer cells, the methods comprising administering at least one C35 antibody and either at least one HER2 or at least one EGFR antibody. In some embodiments, the antibodies are administered with a therapeutic agent. The present invention is further directed to... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20110008324 - Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been... Agent: Mckeon Meunier Carlin & Curfman LLC
20110008323 - Cadherin-11 ec1 domain antagonists for treating inflammatory joint disorders: The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20110008319 - Card domain containing polypeptides, encoding nucleic acids, and methods of use: The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.... Agent: Mcdermott, Will & Emery LLP
20110008320 - Further use of protein kinase n beta: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20110008318 - Toll-like receptor 5 ligands and methods of use: The invention provides an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence GAVQNRFNSAIT, or a modification thereof, and having toll-like receptor 5 (TLR5) binding. Methods of inducing an immune response are also provided.... Agent: Morrison & Foerster LLP
20110008321 - Vectors, host cells, and methods of production and uses: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and... Agent: Philip S. Johnson Johnson & Johnson
20110008326 - Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders: The present invention relates to the use of an antigen-binding agent directed against human interleukin-4 receptor for the prevention and/or treatment of tumors, inflammatory and immunological disorders. Further the invention relates to methods of inhibiting the bioactivity of IL-4 without inhibiting binding of IL-4 to IL-4R and particularly to methods... Agent: Howrey LLP-ca
20110008325 - Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension: An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20110008340 - Anti-properdin antibodies: A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the N terminus end of properdin effective to the inhibit alternative complement pathway in the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.
20110008332 - Combination therapy to treat persistent viral infections: The present invention pres ides combination therapies to treat persistent viral infections. In particular, combinations of vaccines and IL-10 or IL-10 receptor (IL-10R) antagonists to clear such infections are provided.... Agent: Merck C/o Dnax
20110008330 - Compositions and methods of tolerizing a primate to an antigen: Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing... Agent: Carella, Byrne, Cecchi, Olstein, Brody & Agnello
20110008327 - Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent: Fanelli Strain & Haag PLLC
20110008328 - Method for controlling glucose uptake and insulin sensitivity: The invention provides methods for treating diabetes and related disorders, such as metabolic syndromes (which includes insulin resistance), by administering an inhibitor of osteopontin (OPN), which includes an antibody, antibody fragment, siRNA, and aptamer. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an... Agent: Connolly Bove Lodge & Hutz LLP
20110008335 - Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds: The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20110008333 - Methods of inhibiting unwanted cell proliferation using hedgehog antagonists: The present application is directed to compositions and methods for inhibiting angiogenesis and treating or preventing unwanted cell proliferation, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein.... Agent: Ropes & Gray LLP Iprm - Floor 43
20110008329 - Methods of treating rsv infections and related conditions: The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease... Agent: Medimmune, LLC Patrick Scott Alban
20110008339 - Monoclonal antibody and use thereof: e
20110008334 - Nogo-a binding with enhanced affinity and pharmaceutical use thereof: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342-357 with a dissociation constant, 1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide capable of producing a binding molecule;... Agent: Novartis Corporate Intellectual Property
20110008336 - Treatment of autoimmune diseases: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.... Agent: Sidley Austin LLP
20110008337 - Treatment of autoimmune diseases: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.... Agent: Sidley Austin LLP
20110008338 - Treatment of autoimmune diseases: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.... Agent: Sidley Austin LLP
20110008331 - Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response: The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an... Agent: Harness, Dickey & Pierce, P.L.C
20110008342 - Compositions of humanized notch fusion proteins and methods of treatment: This invention provides a fusion protein comprising a single peptide, an extracellular domain of human Notch receptor protein and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method... Agent: Cooper & Dunham, LLP
20110008341 - Polypeptides and methods for making the same: i
20110008344 - Fusion partner cell line for preparation of hybrid cells expressing human antibodies: This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20110008343 - Method of reducing tissue loss in pancreatic islet cell transplantation: Methods for reducing rejection of pancreatic islet cells transplanted into a subject are disclosed. The methods involve transplanting pancreatic islet cells into a subject in the presence of a complement inhibitor, alone or combined with dextran sulfate.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.
20110008345 - Antigen-binding constructs: The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a... Agent: Glaxosmithkline Global Patents -us, Uw2220
20110008346 - Biomarkers for cardiovascular disease: The present invention relates to a method of diagnosis or prognosis of cardiovascular disease in a subject, said method comprising the steps of detecting the presence of activated endothelial progenitor cells (EPCs) in a sample of a circulation fluid of said subject. The invention further relates to biomarkers for diagnosis... Agent: Reed Smith LLP
20110008355 - Anti-flt3 antibodies: The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including... Agent: Eli Lilly & Company
20110008354 - Antibodies to apo-2 receptor polypeptides: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.... Agent: Sidley Austin LLP
20110008351 - Anticomplement polypeptides of ixodes ricinus: An isolated and purified polypeptide is obtained from tick salivary glands and presents more than 75% sequence identity with at least a sequence selected from the group consisting of SEQ. ID. NO. 1.... Agent: Merchant & Gould PC
20110008347 - Cancer-related protein kinases: The present invention relates to mutant kinase polypeptides and kinase variants selected from the group consisting of AATYK (AATK), ABL1, ACK1, ALK, ARG, AXL, BMX, BRK, BTK, CCK4, CSFR1, CSK, DDR1, DDR2, EGFR, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA10, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, FAK, FER, FES, FGFR1,... Agent: Foley & Lardner LLP
20110008350 - Extracellular targets for alzheimer's disease: The present invention relates to the field of neurological disorders and more particularly to the field of Alzheimer's disease. Specifically, the invention provides extracellular targets for Alzheimer's disease selected from the tetraspanin web family and associated proteins. In addition, methods are provided for the use of siRNAs and antibodies against... Agent: Traskbritt, P.C.
20110008349 - Hypoxia induced mitogenic factor: We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor... Agent: Banner & Witcoff, Ltd.
20110008353 - Identification of astrovirus va1 associated with gastroenteritis in humans: Provided herein is a novel human astrovirus, its nucleic acid sequence, as well as methods to detect and diagnose the presence of the astrovirus.... Agent: Morrison & Foerster LLP
20110008348 - Soluble fragments of influenza virus pb2 protein capable of binding rna-cap: A plastic container includes an upper portion having a mouth defining an opening into the container. A shoulder region extends from the upper portion. A sidewall portion extends between the shoulder region and a base portion. The base portion closes off an end of the container. A vacuum panel region... Agent: Baker & Daniels LLP
20110008352 - Toll-like receptor 3 antagonists: Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.... Agent: Philip S. Johnson Johnson & Johnson
20110008357 - Antibodies that bind il-18 and methods of inhibiting il-18 activity: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of... Agent: Mccarter & English, LLP / Abbott Laboratories Ltd.
20110008358 - Human monoclonal antibodies that specifically bind igf-ii: Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth... Agent: Klarquist Sparkman, LLP (ott-nih)
20110008356 - Il-17 heteromeric receptor complex: The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active.... Agent: Amgen Inc. Law Department
20110008359 - Monoclonal antibodies against angptl4: Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.... Agent: Andrus, Sceales, Starke & Sawall, LLP
20110008360 - Human antibodies against rabies and uses thereof: Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.... Agent: Nelson Mullins Riley & Scarborough LLP Floor 30, Suite 3000
20110008362 - Anti-gluten egg yolk antibodies for the treatment of celiac disease: The present invention relates to compositions for ameliorating the symptoms of celiac disease or gluten sensitive enteropathy comprising egg yolk antibodies against gluten, including gliadin, high molecular glutenin, low molecular glutenin and mixtures of the three peptides. The antibodies may be produced by immunizing laying hens with immunogenic preparations of... Agent: Edward Yoo C/o Bennett Jones
20110008361 - Treatment method: A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.... Agent: Knobbe Martens Olson & Bear LLP
20110008364 - Antibodies to tgf-beta: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments... Agent: Ropes & Gray LLP
20110008363 - Erythropoietin variants: The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS)... Agent: Millen, White, Zelano & Branigan, P.C.
20110008365 - Methods of treating scleroderma: The present invention relates to methods for treating/ameliorating seleroderma and associated symptoms.... Agent: Medimmune, LLC Patrick Scott Alban
20110008367 - Anti-vegf antibody: An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to... Agent: Bozicevic, Field & Francis LLP
20110008366 - Inhibition of versican with sirna and other molecules: The present invention provides methods of treating disease or condition in a subject in need thereof, comprising administering the subject a versican inhibitor in an amount effective to treat the disease or condition. Example diseases or conditions include, but are not limited to, fibrotic disease such as fibrotic lung disease,... Agent: Myers Bigel Sibley & Sajovec
20110008368 - Methods of modulating the ox40 receptor to treat cancer: Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX4OL. OX4OL inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX4OL is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand.... Agent: NielsenIPLaw LLC
20110008369 - Pd-1 binding proteins: The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.... Agent: Merck
20110008372 - Enhancement of light activated drug therapy through combination with other therapeutic agents: The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the... Agent: Law Offices Of Ronald M Anderson
20110008371 - Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method... Agent: Jones Day
20110008370 - Novel use of flj25416 gene: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20110008373 - Prodrugs of cc-1065 analogs: Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a... Agent: Sughrue Mion/immunogen
20110008374 - Use of il-1 antagonists to treat gout: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.... Agent: Regeneron Pharmaceuticals, Inc
20110008375 - Uses of myostatin antagonists: The present invention provides methods for treating disorders arising from hypogonadism, rheumatoid cachexia, cachexia due to burns, cachexia due to administration of chemical agents, cachexia due to diabetes, diabetic nephropathy, Prader Willi syndrome, excessive TNF-α, and other muscle-related, metabolic and inflammatory disorders by administering myostatin antagonists to subjects suffering from... Agent: Amgen Inc.
20110008376 - Immunogenic compositions capable of activating t-cells: The invention provides means and methods for producing and/or selecting immunogenic compositions capable of activating a T-cell and/or a T-cell response, comprising providing said composition with at least one crossbeta structure and testing at least one immunogenic property.... Agent: Traskbritt, P.C.
20110008377 - Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides: The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed... Agent: Loeb & Loeb LLP
20110008380 - Anaplasma phagocytophilum (aph) antigens and antibodies specific for anaplasma: The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20110008379 - Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof: Immunogenic compositions containing Escherichia coli O157:H7 flagella including fusion proteins and methods using the immunogenic compositions are disclosed. Inducing an immune response in an animal to Escherichia coli O157:H7 flagella will result in prevention of colonization by Escherichia coli O157:H7 in the animal or a reduction in the amount of... Agent: Foley And Lardner LLP Suite 500
20110008378 - Modified flagellin improved toll-like receptor 5 stimulating activity: Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.... Agent: Sughrue Mion, PLLC
20110008381 - Suppression of allergic inflammation by ascaris heme-binding protein (hbp): This invention relates, e.g., to a method for suppressing inflammation (e.g. allergic inflammation, for example asthma caused by ragweed), a Th1-mediated condition and/or a Th2-mediated condition and/or a condition in which administration of an antioxidant would be beneficial, in a subject in need thereof, comprising administering to the subject an... Agent: Ott- Nih C/o Woodcock Washburn LLP
20110008382 - Compositions and methods using recombinant mhc molecules for the treatment of uveitis: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and... Agent: Klarquist Sparkman LLP
20110008383 - Compositions of toll-like receptor agonists and malaria antigens and methods of use: Compositions that include at least one fusion protein that includes at least a portion of at least one flagellin and at least a portion of at least one malaria antigen can be employed in methods that stimulate an immune response in a subject, in particular, sterile immunity and a protective... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20110008384 - Antiviral activity from medicinal mushrooms: Compounds having unique antiviral properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis and blends of medicinal mushroom species and are useful in preventing and treating viruses including Poxviridae and Orthopox viruses.... Agent: William R. Hyde
20110008385 - Immunogenic composition: The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from S. aureus. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.... Agent: Nixon & Vanderhye, PC
20110008386 - Use of mva to treat prostate cancer: The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or... Agent: Bn Immuno Therapeutics, Inc.
20110008387 - Composition containing hcmv particles: The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20110008388 - Piglet feed rations having low levels of fermentable carbohydrates: The present invention provides compositions comprising at least one acidifying agent, at least one immune stimulating agent, at least one antioxidant, and optionally, at least one tissue regeneration agent. The compositions comprise pre-mixes for inclusion in the diets of piglets, wherein the diets have low levels of fermentable carbohydrates.... Agent: Polsinelli Shughart PC
20110008389 - Recombinant attenuated clostridium organisms and vaccine: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also... Agent: Merck Patent Department (k-6-1, 1990)
20110008390 - Production of a viable, storable worm egg suspension: The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. The T. suis worm eggs are first treated in a non-embryonated condition in a sulfuric acid solution at about=ph 2. Bacteria and viruses are thereby killed successfully. The... Agent: Curatolo Sidoti Co., Lpa
20110008391 - Vaccine composition and immunization method: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.... Agent: Nixon & Vanderhye, PC
20110008392 - Vaccine targets and delivery systems for cryptosporidium: Compositions comprising the Cryptosporidium sporozoite antigens such as SRK (‘similar to riken’), CP15 and profilin are used in vaccines against the protozoan parasite Cryptosporidim.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.
20110008394 - Active substances that increase the activation threshold of immune cells: The present invention relates to the use of active substances that increase the activation threshold of immune cell as an active principle for the preparation of a cosmetic or pharmaceutical composition, especially a dermatological composition. The invention also relates to a method for screening such active substances.... Agent: Basf Beauty Care Solutions France C/o Connolly Bove Lodge & Hutz LLP
20110008393 - Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer: A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or... Agent: Agensys C/o Morrison & Foerster LLP
20110008397 - Compartmental extract compositions for tissue engineering: The present invention concerns biologically-active cell-free scaffolds composed of extracts of cellular and/or extracellular compartments for use in tissue regeneration. The present invention also contemplates the novel concept of redesigning the biological scaffold by seeding cells thereon followed by cell elimination. Cells are seeded on the scaffold for a period... Agent: Brooks Kushman P.C.
20110008396 - Compositions and methods for treating cardiovascular conditions: The invention provides amphiphilic macromolecule encapsulates that are useful for treating cardiovascular diseases including conditions related to or emanating from atherosclerosis.... Agent: Viksnins Harris & Padys Pllp
20110008398 - Medicated patch: Provided is a medicated patch containing a medicinal agent and an adhesive base material and having an acid value of no greater than 28, where the medicinal agent is varenicline or a pharmaceutically acceptable salt of varenicline.... Agent: The Nath Law Group
20110008395 - Mixed micelles including amphipathic conjugates of rna agents, and uses thereof: Disclosed are improved pharmaceutical formulations for the delivery of RNA interference agents, such as antisense RNA, micro-RNA and siRNA. The formulations employ mixed micelles including amphipathic conjugates of the iRNA agents and amphipathic micelle-forming molecules with extended hydrophilic chains. Also disclosed are methods of using the pharmaceutical formulations to increase... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP
20110008401 - Cosmetic compositions for imparting superhydrophobic films: Compositions and methods are disclosed for imparting super-hydrophobic properties to cosmetics, in particular mascaras. The compositions comprise a hydrophobic film former in combination with hydrophobically-modified iron oxide pigments and/or carbon black.... Agent: Avon Products, Inc.
20110008400 - Digital wipes and method of handling: The present invention describes novel dental wipes and novel formulations for treating dental caries. The formulations may be used on the dental wipes or independently from the wipes. The wipe, when applied to the teeth, gums, tongue, and oral mucosa, helps treat dental caries and remove biofilm.... Agent: Nguyen & Tarbet
20110008399 - Use of zero-order diffractive pigments: The present invention relates to compositions such as coatings, printing inks or cosmetics, which contain pigments comprising or consisting of a layer made of a material with an index of refraction that is higher than the index of refraction of the adjacent material by at least 0.25; whereas said layer... Agent: Basf Corporation Patent Department
20110008402 - Souluble b-n-acetylglucoseaminidase based antibiofilm compositions and uses thereof: The present invention provides compositions comprising an antibiofilm enzyme, a soluble β-N-acetylglucosaminidase similar to the dspB gene (DispersinB™), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular,... Agent: Merchant & Gould PC
20110008403 - Medical antimicrobial composition and medical device comprising the same: A medical antimicrobial composition includes a siloxanyl structure-containing polymer and an ammonium group-containing polymer, which is excellent in transparency, flexibility and mechanical properties, and also excellent in adhesion to a base resin with good mechanical properties, particularly to a silicone resin. The medical antimicrobial composition includes an ammonium group-containing polymer... Agent: Ratnerprestia
20110008404 - Modification of biomaterials with microgel films: The various embodiments of the present disclosure relate generally to the modification of biomaterials with microgel films. More particularly, the various embodiments of the present invention are directed to the modification of biomaterials and medical devices with microgel thin films to alter a host's response to an implanted biomaterial or... Agent: Troutman Sanders LLP 5200 Bank Of America Plaza
20110008407 - Coating and coating method: The present invention discloses a coating for a medical implant, wherein at least a part of said coating contains an osseointegration agent and the same and/or a different part of the coating contains an antimicrobial metal agent.... Agent: Diana Houston Smith & Nephew, Inc.
20110008405 - Hollow tubular drug eluting medical devices: A method of a forming a hollow, drug-eluting medical device includes providing composite member having an outer member and a core member disposed within a lumen of the outer member. The composite member is shaped into a pattern. Openings are formed through the outer member of the composite member. The... Agent: Medtronic Vascular, Inc.IPLegal Department
20110008406 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.
20110008408 - Solid dosage form for treating headaches: A retrievable, sustained release, solid dosage form is provided for implanting into cranial bony canals and for prolonged release of an anesthetic, whereby treating neurovascular conditions, such as migraine. The dosage comprises an anesthetic contained in a polymeric carrier, and a retrieval member, the anesthetic being gradually released from the... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.
20110008409 - Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation: The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily... Agent: Millen, White, Zelano & Branigan, P.C.
20110008410 - Pharmaceutical composition for treating malaria: The invention relates to a pharmaceutical composition in the form of rectal capsules, comprising a combination, effective against malaria parasites, of artemisinine or a derivative of artemisinine, particularly artesunate, with piperaquine or a pharmaceutically acceptable salt thereof, particularly piperaquine tetraphosphate, and having high activity against Plasmodium such as, for example,... Agent: Wenderoth, Lind & Ponack, L.L.P.
20110008411 - Method of treating pruritis: The present invention relates to a method of treating dermatologic pruritis. The skin involved with purities is covered with an organic cloth in order to make it more difficult to scratch. The contact of the organic cloth not only makes it difficult to scratch but adds a soothing feel thus... Agent: Passe' Intellectual Property, LLC
20110008412 - Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same: A pharmaceutically acceptable oral formulation comprising core material which comprises a therapeutically effective amount of a 5-HT-receptor agonist, or a pharmaceutically acceptable salt, solvate or derivative thereof, which core material is provided with a substantially water resistant coating comprising one or more substantially water resistant materials.... Agent: Conley Rose, P.C.
20110008413 - Compositions and methods of topical drug delivery for the treatment of carpal tunnel syndrome: The present invention generally relates to transdermal drug delivery systems. More particularly, the present invention provides compositions and transdermal drug delivery systems for the treatment and/or relief of symptoms associated with carpal tunnel syndrome or tendonitis.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20110008416 - Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.... Agent: Birch Stewart Kolasch & Birch
20110008418 - Compositions and methods for the treatment of cancer: wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR′, N(R″)2, C(O)R′″, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where... Agent: Thorpe North & Western, LLP.
20110008417 - Immunomodulating compositions and uses therefor: This invention discloses compositions that consist essentially of a Gag polypeptide or at least one portion thereof, and optionally antigen-presenting cells or their precursors, for treating or preventing lentiviral infections including the treatment or prevention of related acquired immunodeficiency diseases. In certain embodiments, the compositions consist essentially of a plurality... Agent: Knobbe Martens Olson & Bear LLP
20110008421 - Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye: The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and/or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 μm or... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.
20110008414 - Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines: The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further... Agent: Proskauer Rose LLP
20110008415 - Novel lipophilic compositions and uses thereof: New co-lipids for use in combination with lipophilic compounds as nucleic acid vectors, for preparing a nucleic acid vector composition, and methods for introducing in vitro or in vivo a nucleic acid of interest into host cells, including a step of contacting host cells these nucleic acid vector compositions. The... Agent: Young & Thompson
20110008420 - Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide: An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range... Agent: Stetina Brunda Garred & Brucker
20110008422 - System for delivery of protein in insoluble fibrillar or aggregate form: A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or aggregates of the therapeutic protein in the pharmaceutical composition are encapsulated in a lipidated glycosaminoglycan particle, coated with a multi-layer of lipids and lipid-glycosaminoglycan conjugates, or... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20110008419 - Vaccine against streptococcus pneumoniae: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from Streptococcus pneumoniae selected from the group consisting of PhtA, PhtD, PhtB, PhtE, SpsA,... Agent: Glaxosmithkline Global Patents
20110008423 - Pharmaceutical compositions comprising granules of purified microbial lipase and methods for preventing or treating digestive disorders: The present invention relates to pharmaceutical compositions comprising granules containing at least one recombinantly produced purified microbial lipase, the use of said pharmaceutical compositions for the manufacture of a medicament for the prevention or treatment of certain diseases or disorders like pancreatic endocrine insufficiency, and a process for the manufacture... Agent: Mayer Brown LLP
20110008424 - Sustained release solid formulations and methods of manufacturing the same: Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type excipient and copovidone, and thus, has increased compressibility and fluidity and reduced adhesiveness, and a method of preparing the same.... Agent: The Webb Law Firm, P.C.
20110008426 - Modified release pharmaceutical compositions comprising mycophenolate and processes thereof: Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof, wherein the said composition exhibits a biphasic release profile when subjected to in-vitro dissolution and/or upon administration in-vivo are provided. The composition provides a drug release... Agent: Ladas & Parry LLP
20110008425 - Treatment for attention-deficit hyperactivity disorder: A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided.... Agent: King & Spalding
20110008427 - Microcapsules and methods: The present invention relates to microcapsules and methods for the production of microcapsules using sterically stabilized colloidal particles wherein the microcapsule comprises a core and a shell and wherein the shell comprises a layer of sterically stabilised colloidal particles and is characterized by the fact that the microcapsule has a... Agent: Conley Rose, P.C. David A. Rose
20110008428 - Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic: The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention... Agent: Smith Patent Consulting, LLC
20110008429 - Anti-retroviral combination: e
20110008430 - Solid pharmaceutical dosage form: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable... Agent: Paul D. Yasger Abbott Laboratories
20110008432 - Method for treating a patient in need of aspirin therapy: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid... Agent: Law Office Of Michael A. Sanzo, LLC
20110008431 - Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia: The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia according to the present invention is characterized in comprising buprenorphine hydrochloride, having a double layer structure consisting of a quick-release layer... Agent: Leydig Voit & Mayer, Ltd
20110008433 - Herbal composition for osteoarthritis: A novel herbal composition comprising of Lactuca sativa L., Aquilariae resinatum Lignum, Oryza sativa L., Boswellia carterii Birdw, Rhizoma atractylodis macrocephalae and Semen cuscutae is useful in treating osteoarthritis.... Agent: Sinorica, LLC
20110008434 - Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile: The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.... Agent: Philip S. Johnson Johnson & Johnson
20110008438 - Bone repair composition and a method of making the same: Bone repair composition and method of making the same, the bone repair composition being formed by firstly mixing a first aqueous calcium phosphate suspension with bone graft granules to form an intermediate mixture. The intermediate mixture is then mixed with a second aqueous calcium phosphate suspension, wherein the first aqueous... Agent: Licata & Tyrrell P.C.
20110008435 - Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds: The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000... Agent: Fox Rothschild, LLP Elan Pharma International Limited
20110008436 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.
20110008437 - Silk fibroin hydrogels and uses thereof: The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents,... Agent: Allergan, Inc.
20110008442 - Dendritic macroporous hydrogels prepared by crystal templating: The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with... Agent: Chalker Flores, LLP
20110008439 - Duloxetin composition: The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt.... Agent: Arent Fox LLP
20110008440 - Novel nanocompound materials with infrared, ultraviolet and visible electromagnetic radiation blocking properties and method for obtaining them: The present invention refers to novel nanocomposite materials with protection properties against infrared and ultraviolet-visible radiation, to the method for obtaining them, which comprises the stages of reducing the size of the laminar particles by mechanical action, filtering, removing organic matter, removing crystalline oxides and hard particles that are not... Agent: Merchant & Gould PC
20110008441 - Thermoresponsive arginine-based hydrogels as biologic carriers: Cationic poly(ester amide) (PEA)-based hydrogels are provided. The hydrogels are fabricated from unsaturated L-arginine base poly(ester-amide) (UArg-PEA) precursors, pluronicDA precursors, or a combination of UArg-PEA and pluronicDA precursors at predetermined precursor composition ratios. PluronicDA/UArg-PEA hybrid hydrogels and pure pluronicDA based hydrogels are thermoresponsive and biodegradable, while pure UArg-PEA base hydrogels... Agent: Marjama Muldoon Blasiak & Sullivan LLP
20110008444 - Composition for the formation of gels: b) a formulation of a homo-multifunctional cross-linking reagent (CLR-formulation) exhibiting a plurality of a reactive group (reactive CLR-group). The two reactive groups are selected as a pair of counterparts that mutually and selectively react with each other to form a linkage structure. The hydrogel contains a cross-linking structure which a)... Agent: Young & Thompson
20110008443 - Photocrosslinked biodegradable hydrogel: A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP
20110008447 - Carrier comprising nanodiamond: The present invention provides a carrier including a nanodiamond (ND) particle and a linker covalently bound to the ND particle, in which the linker is presented by the formula: —R1—O(R2)m-Q-. In addition, the present invention further provides a carrier having an active unit covalently bound to the linker, in which... Agent: Edwards Angell Palmer & Dodge LLP
20110008448 - Diketopiperazine salts for drug delivery and related methods: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described... Agent: K&l Gates LLP
20110008446 - Method of drug delivery: A drug delivery method for effective drug application is disclosed in this invention. In this method, a micro-carrier delivers an encapsulated, desired drug directly to targeted sites without significant interactions with other components in the biological system in the pathway. In one embodiment, a micro-carrier containing encapsulated drug is first... Agent: Joseph F. Gula, Iii
20110008445 - Suspension of ascorbic acid in glycerin and process for production thereof: A suspension of ascorbic acid in glycerol or in glycerol comprising diglycerol, in which the content of ascorbic acid is 13% by mass or greater, and further in which 8 to 12% by mass of the ascorbic acid is dissolved in glycerol or in glycerol comprising diglycerol, and the rest... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110008451 - Compositions and methods for controlled delivery of inhibitory ribonucleic acids: Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nanoparticles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs... Agent: Pabst Patent Group LLP
20110008449 - Human specific escherichia coli strains: The present invention relates to human specific Escherichia coli strains.... Agent: Mcandrews Held & Malloy, Ltd
20110008450 - Slow release compositions: The present invention relates to the provision of micron or sub-micron sized particles formed from one or more water-soluble crystals comprising a surface coating comprising one or more bioactive molecules wherein the particles are prepared such that in use the release of the bioactive molecule(s) is/are delayed and/or continually released... Agent: Alston & Bird LLP
20110008455 - Crosslinked protein nanocrystals, crosslinked protein nanoaggregates and method of preparation thereof: This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of protein nanoparticle precursor materials—i.e., crosslinked proteins of the micron or greater size—via mechanical or hydrodynamic shear, mechanical crushing, sonic cavitation and/or hydrodynamic... Agent: Intellectual Property Law Group LLP
20110008454 - Immediate release pharmaceutical granule compositions and a continuous process for making them: A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from 0.5% to 20% by weight of the composition, and excipients, said pharmaceutical... Agent: Clark & Elbing LLP
20110008452 - Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance: The inventive medicinal agent comprises antibodies against beta-subunit of insulin receptor in an activated form produced by means of repeated serial dilution and an external action performed according to homeopathic technology. The inventive method for producing a solid medicinal formulation for perorally treating fatness, diabetes, and other diseases associated with... Agent: Kaplan Gilman & Pergament LLP
20110008453 - Stable corticosteroid nanoparticulate formulations and methods for the making and use thereof: Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.... Agent: Davidson, Davidson & Kappel, LLC
20110008456 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent: Wilson, Sonsini, Goodrich & Rosati
20110008457 - Compositions and methods for modulating lipid composition: The present subject matter relates to a novel herbal and oil composition and methods for modulating fatty acid composition and metabolism in an animal. In one aspect, the subject matter involves a composition comprising rosemary extract, oregano extract, and a polyunsaturated oil. In a particular embodiment, the polyunsaturated oil is... Agent: The Nath Law Group
20110008458 - Process for removing growth factors from platelets: A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to... Agent: Price & Adams, P.C.
20110008459 - Universally applicable blood plasma: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.... Agent: Jacobson Holman PLLC
20110008460 - Biomimetic hydroxyapatite composite materials and methods for the preparation thereof: The present invention is related to methods for preparing composite materials, which include nanoscale hydroxyapatite, and the composite materials and articles prepared therewith.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20110008461 - Inhibitor scaffold for the inhibition of the enzyme phosphoenolpyruvate carboxykinase: A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b)... Agent: Workman Nydegger 1000 Eagle Gate Tower
20110008462 - System and method for therapeutic application of dissolved oxygen: A system and method for generating an oxygen enriched aqueous solution for therapeutic application includes a diffuser comprising a first diffusing member having a surface incorporating surface disturbances, and a second diffusing member positioned relative to the first diffusing member to form a channel through which an aqueous solution and... Agent: Davis Wright Tremaine, LLP/seattle
20110008463 - Combinations of hydroxypyrion compounds and silver compounds: The present invention relates to combinations of hydroxypyrion compounds, and silver compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a hydroxypyrion compound selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone, piroctone olamine, rilopirox, or a salt thereof, together with one... Agent: Philip S. Johnson Johnson & Johnson
20110008464 - Methods and compositions for treating thyroid-related medical conditions with reduced folates: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which... Agent: Brett Bartel
20110008465 - Sesquiterpene formulations, kits and methods of use thereof: A pharmaceutical composition comprising a water insoluble sesquiterpene, one or more antioxidants and one or more solubilizers selected from the group consisting of an oil, PEG400, a derivative of castor oil and ethylene oxide, and polysorbate 80, and methods of use thereof.... Agent: Goudreau Gage Dubuc
20110008466 - Methods and compositions for altering cell function: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX), when administered... Agent: Casimir Jones, S. C.
20110008467 - Sodium thiosulfate-containing pharmaceutical compositions: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration... Agent: Jones Day
20110008468 - Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders: Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or... Agent: Wolf Greenfield & Sacks, P.C.
20110008469 - Antimicrobial composition and methods and apparatus for use thereof: There is presented an alkaline disinfectant in the form of a multi-component composition, with each component being relatively benign until mixed with the other components in a ready-to-use solution. The invention further relates to the use of the composition in a variety of applications and apparatus for mixing and dispensing... Agent: Hahn Loeser & Parks, LLP
20110008470 - Carrageenan modified by ion-exchange process: A composition comprises an ion-exchanged carrageenan. The carrageenan may be a traditionally extracted or neutrally extracted iota or kappa carrageenan. The ion-exchanged carrageenan has reduced gelling cation contents, reduced gelling temperature, and reduced melting temperature, as compared to its non-ion-exchanged counterpart. The ion-exchanged carrageenan may be mixed with another carrageenan... Agent: Cp Kelco Us, Inc C/o Pete Pappas, Sutherland, Asbill & Brennan LLP
20110008472 - Anti-methicillin-resistant staphylococcus aureus agent and anti-vancomycin-resistant enterococcus agent: An anti-methicillin-resistant Staphylococcus aureus agent (anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (anti-VRE agent) contain as an active ingredient an Oobagi extract extracted from Oobagi with an extraction solvent including at least an organic solvent. Alternatively, the anti-MRSA agent and the anti-VRE agent contain as an active ingredient at least... Agent: Seager, Tufte & Wickhem, LLC
20110008471 - Synergistic antiparasitic compositions and screening methods: Compositions for treating parasitic infections and methods of using the compositions to treat subjects with parasitic infections are provided. Methods of selecting compositions for use in treating parasitic infections are further provided.... Agent: Davis Wright Tremaine LLP - San Francisco
20110008473 - Use of hypericum perforatum extracts in the treatment of neuropathic pain: Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.... Agent: Arent Fox LLP
20110008474 - Topical antifungal composition: A composition obtained primarily from plant materials provides antimicrobial activity for use as an anti-fungal agent. The anti-fungal agent is effective in inhibiting the growth of Trichophyton rubrum, the fungus that is the most common cause of Tinea pedis. The composition includes selective mixtures of the origanum oil, menthol, and... Agent: Frost Brown Todd, LLC
20110008475 - Use of an emulsion of mint oil or of l-carvone for the fungicidal treatment of fruit, vegetables or plants: The present invention relates to novel emulsions of mint oil and/or L-carvone and the use thereof for the fungicidal treatment of field crops or products thereof.... Agent: Jacobson Holman PLLC
20110008476 - Methods of treating or preventing inflammatory diseases of the intestinal tract: The present invention relates to a glucan derived from yeast having a beta-(1, 3)-backbone with one or more beta-(1, 3)-side chains linked thereto for use in the treatment or prevention of inflammatory bowel disease and related diseases of abnormal bowel function in an animal, in particular to such uses employing... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.01/06/2011 > 180 patent applications in 112 patent subcategories. recently filed with US Patent Office
20110002843 - Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm: This invention is directed to myocardial imaging of human patients having a history of asthma or bronchospasm. In particular, the present invention uses binodenoson as a pharmacological stressor in conjunction with any one of several noninvasive and invasive diagnostic procedures available. For example, intravenous administration may be used in conjunction... Agent: King Pharmaceuticals, Inc.
20110002844 - Stabilization of macromolecular membranes: Disclosed are stabilized polymersomes having layer structures. Such stabilized polymersomes are, in some embodiments, biocompatible, and are capable of enhanced, sustained release of agents. Also disclosed are related methods for synthesizing such stabilized polymersomes and methods for using such polymersomes for delivery of therapeutic, imaging, and various other agents.... Agent: Woodcock Washburn LLP
20110002846 - Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain: The present invention is directed to methods of treating a primary brain tumor and preventing the migratory spread of a primary brain tumor in a subject. These methods involve utilizing the CD24 surface protein selectively expressed on tumor progenitor cells as a therapeutic target as well as a means for... Agent: Nixon Peabody LLP - Patent Group
20110002845 - Methods of treating, diagnosing or detecting fgf21-associated disorders: The invention provides, inter alia, methods for treating cancer and vascular disease, compositions for treating cancer and vascular disease, and methods and compositions for diagnosing and/or detecting cancer and vascular disease.... Agent: Novartis Institutes For Biomedical Research, Inc.
20110002847 - Method of forming an injectable radioactive composition of a carbon encapsulated radioactive particulate: A method of forming an injectable radioactive composition, the method comprising the steps of: (a) depositing a solid form of technetium onto a carbon crucible; (b) preheating the solid form of technetium to remove any carrier; (c) plasma ablating the technetium and portions of the carbon crucible; (d) allowing the... Agent: Townsend And Townsend And Crew, LLP
20110002848 - Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further... Agent: Mcdermott, Will & Emery LLP
20110002849 - Therapy selection method: The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2,... Agent: Ge Healthcare, Inc.
20110002850 - Nitro-imidazole hypoxia imaging agent: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging... Agent: Siemens Corporation Intellectual Property Department
20110002851 - Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases: The present invention relates to the use of cationic colloidal compositions for the targeted delivery of an active compound to an inflammatory site or an activated vascular site for the preparation of a medicament for the treatment of MS and in general for all CNS or PNS inflammatory neurodegenerative and... Agent: Morgan Lewis & Bockius LLP
20110002852 - Stem cells for use in locating and targeting tumor cells: A composition for locating tumors, the composition includes stem cells. Stem cells for use in locating and treating tumors. A method of locating and treating a tumor by administering to a patient an effective amount of stem cells, wherein the stem cells locate and subsequently treat a tumor.... Agent: Rader, Fishman & Grauer PLLC
20110002856 - Compositions containing volatile solvents:
20110002855 - Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues: Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues of the formula (I): are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of... Agent: Cantor Colburn LLP
20110002854 - Use of francisella tularensis for prevention and treatment of allergic airway disorders: A pharmaceutical composition for treating or preventing a Th2-mediated disease or disorder includes live, killed or attentuated Franciscella tularensis or its components. The F. tularensis cells may be LVS cells. Administration of an effective amount may prevent or reduce bronchoconstriction or allergic airway inflammation through a T-helper cell (Th) 1-mediated... Agent: Edward Yoo C/o Bennett Jones
20110002857 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein... Agent: Wilmerhale/boston
20110002859 - Chewing gum containing eucalyptus extract: It is an object of the present invention to provide a chewing gum, by which an effect of preventing periodontal disease is obtained through mastication without performance required for a chewing gum being impaired, such as taste, appearance, and physical properties and storage stability as a product. A chewing gum... Agent: Miles & Stockbridge PC
20110002858 - Oral compositions for absorption of phosphorous compounds: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from... Agent: Blank Rome LLP
20110002860 - Tooth-bleaching preparations: The present invention relates to a tooth bleaching preparation comprising an adduct formulated from starting materials comprising peroxide, urea and an alkali metal polyphosphate, the adduct being provided in the preparation in aqueous conditions and the preparation having a pH in aqueous solution which rises on dilution of the solution.... Agent: Andrews Kurth LLP
20110002861 - Composition comprising pure aloe and its use as a cosmetic base: A composition to be used as a base for cosmetic products, comprising aloe gel from 50% to 99% by weight and an emulsifier comprising an acryloyl taurate copolymer, a non-ionic surfactant consisting of an ester of sorbitol polyethoxylate, and an oil of natural origin. The use of the composition described... Agent: Modiano & Associati
20110002862 - Method for the production of polymers by means of ion exchange: where R1 is hydrogen, methyl, or ethyl, A is C1-C8-alkylene, Q+ is H+, NH4+, Na+, K+, ½ Mg++, ½ Ca++, or ½ Zn++, and where Q+ has a different meaning than H+ or NH4+ in 50 to 100 mol % of the structural units of formula (1), and one or... Agent: Clariant Corporation Intellectual Property Department
20110002864 - Composition containing a tackifying resin and a combination of particular oils: A composition having at least one fatty phase containing at least one resin having a number-average molecular weight of less than or equal to 10 000 g/mol chosen from rosin, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, at least one volatile oil, and at least one phenyl silicone oil.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110002865 - Moisturizing cosmetic composition comprising a combination of homarine and erythritol: The subject matter of the present invention is a cosmetic or dermopharmaceutic composition comprising a combination of homarine and erythritol as well as a non-therapeutic treatment method of the skin to improve cutaneous hydration, to prevent and/or treat cutaneous dryness signs, to restore and/or protect the cutaneous barrier function, to... Agent: Jones Day
20110002867 - Vinyl ether silicone polymers: The present invention is directed to a series of vinyl ether based silicone polymers and their use in personal care applications. They are prepared by the hydrosilylation reaction of a vinyl ether and a silanic hydrogen compound. The compounds find use in personal care applications.... Agent: Anthony J O'lenick Jr
20110002868 - Cationic synthetic polymers with improved solubility and performance in surfactant-based systems and use in personal care and household applications: The present invention is related to surfactant-based formulations comprising the polyelectrolytes and blends of such polyelectrolytes with non-cellulosic cationic polysaccharide polymers. The surfactant-based formulations exhibit improved clarity of the resulting formulations, their improved conditioning of keratin substrates, textile substrates, and hard-surface substrates, their improved deposition of dispersed phase materials onto... Agent: Wood , Herron & Evans, LLP (hercules)
20110002866 - Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent: The described invention relates to delivery of compositions comprising at least one prostaglandin analog to prevent or reduce hair loss (e.g. brittle hair growth, thin hair growth, short hair growth, sparse hair growth) or alopecia associated with chemotherapy.... Agent: Greenberg Traurig, LLP
20110002871 - Adhesive agent for application on a sanitary object: The invention relates to an agent for sanitary facilities, said agent being applied directly on the sanitary object and adhering there, and being flushable only after a large number of flushes, wherein the agent comprises fillers and a bonding agent, wherein the bonding agent is selected from the group of... Agent: Kriegsman & Kriegsman
20110002870 - Composition of a material with a porous structure comprising a silicate and a carbonate, hydroxide or oxide of alkaline or alkalinoterrous elements, and corresponding preparation methods and uses: Materials with a porous structure including calcium carbonate and magnesium carbonate of mineral origin or from algae or pieces of mollusc shells, formed mainly by together with clays of the bentonite, a-sepiolite and aluminium silicate type. Their industrial use in the removal of acid gases and vapors in fixed and... Agent: Staas & Halsey LLP
20110002872 - Fatty acid metal salt for forming ultrafine metal particles: (iii) a metal of an atomic weight of 50 to 200 is contained, and the amount of the unreacted substance or the by-product is 4.0 mol % or less when the fatty acid metal salt is formed. The fatty acid metal salt can be favorably used for forming ultrafine metal... Agent: Greenblum & Bernstein, P.L.C
20110002873 - Skin cosmetic: i
20110002874 - Polymer network compositions and associated methods: Biomimetic polymer networks comprising a heteropolymer network having a cavity, the cavity having a selective affinity for a moiety, methods for making biomimetic polymer networks, and methods for using biomimetic polymer networks.... Agent: Chalker Flores, LLP
20110002875 - Method for treating amyloidosis: Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such... Agent: Mccarter & English/ Neurochem
20110002876 - Multimeric vla-4 antagonists comprising polymer moieties: Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20110002877 - Pten inhibitors treat neutropenia-associated pneumonia: Neutropenia-associated pneumonia is treated with a therapeutically effective amount of a small-molecule PTEN inhibitor. The method may further include detecting a resultant alleviation of the neutropenia-associated pneumonia, and/or diagnosing the neutropenia-associated pneumonia. The patient may be undergoing anti-cancer chemotherapy and/or radiotherapy, and the methods may further include the step of... Agent: Richard Aron Osman
20110002878 - Scented soil for hunting and trapping: The present invention is directed toward a wax and scent impregnated soil for use in hunting and trapping. The soil is dried and mixed with wax and a scent such as the urine of a target species. The wax makes the soil water resistant and prevents it from freezing. In... Agent: Hornkohl Intellectual Property Law, P.l.l.c
20110002879 - Combinations of pyrazole kinase inhibitors: e
20110002880 - Material for wound healing and skin reconstruction: The invention relates to a material for wound healing and skin reconstruction containing a peptide, wherein the peptide is a self-assembling peptide which is an amphiphilic peptide having 8 to 200 amino acid residues with periodic repeats of alternating hydrophilic amino acids and hydrophobic amino acids, and forms a stable... Agent: Rahman LLC
20110002882 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department
20110002883 - Therapeutic preparations containing wharton's jelly: Therapeutic preparations for rejuvenation and anti-aging of human skin incorporates Wharton's Jelly or substantial fractions thereof as an active ingredient.... Agent: Ladas & Parry LLP
20110002881 - Treatment and prophylaxis: This invention discloses the use of an E-selectin antagonist in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular useful for prophylaxis and/or treatment of hematopoietic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments... Agent: Schwegman, Lundberg & Woessner, P.A.
20110002884 - Therapeutic compounds: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and... Agent: Merck
20110002885 - Methods of using isolated recombinant polypeptide antagonists of sdf-1: This invention is generally directed to a recombinant method of producing SDF-1 receptor antagonists. More particularly, the invention is directed to the isolated and/or recombinant polynucleotide sequences encoding analogs of human SDF-1 alpha or beta and, in particular, SDF-1 analogs having the proline at residue position number 2 replaced with... Agent: Perkins Coie LLP
20110002888 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110002887 - Combinations of antibodies selective for dr5 and other therapeutic agents: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease... Agent: Mckeon Meunier Carlin & Curfman LLC
20110002886 - Tetrahydrofuro [3,4-d] dioxolane compounds for use in the treatment of viral infections and cancer: The invention provides compounds of formula (I), as described herein, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula (I) are useful as anti-viral agents and/or as anti-cancer agents.... Agent: Viksnins Harris & Padys Pllp
20110002889 - Cultures with improved phage resistance: The present invention provides methods and compositions related to modulating the resistance of a cell against a target nucleic acid or a transcription product thereof. In some preferred embodiments, the present invention provides compositions and methods for the use of one or more cas genes or proteins for modulating the... Agent: Danisco US Inc. Attention: Legal Department
20110002890 - Treatment of tumors with genetically engineered herpes virus: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.... Agent: Marshall, Gerstein & Borun LLP
20110002891 - Probiotic compositions and process thereof: Probiotic composition(s) and/or process(es) thereof. Processes may include applying Janthinobacterium, for example Janthinobacterium lividum, over a host and/or host area(s) to minimize microbe(s) and/or maximize therapeutic effects. A process to minimize a microbe may include applying to skin a composition including isolated Janthinobacterium lividumand a pharmaceutically acceptable carrier. Probiotic composition(s)... Agent: Sherr & Vaughn, PLLC
20110002900 - Medium chain dicarboxylic acids, their derivates and metabolic disorders: The present invention relates in general to medium chain dicarboxylic acids, their derivatives and their uses. In particular, the present invention relates to a composition comprising medium chain dicarboxylic acids and to the use of medium chain dicarboxylic acids and their derivatives for the preparation of products to treat or... Agent: Gerber Products Company
20110002901 - Bacterial strain having anti-allergic activity, and beverage, food and anti-allergic agent comprising cell of the bacterial strain: It is an object of the present invention to provide a bacterial strain belonging to Lactobacillus brevis subspecies brevis, which has more potent antiallergic activity than the known lactic acid bacteria strains and produces γ-aminobutyric acid (GABA). It is another object of the present invention to provide beverages and foods... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110002902 - Inhibitor for blood phosphorus level elevation: The present invention provides an inhibitor for blood phosphorus level elevation comprising a lactic acid bacterium as an active ingredient. The inhibitor for blood phosphorus level elevation of the present invention is highly safe, is readily administerable, and can sufficiently inhibit a blood phosphorus level elevation.... Agent: Renner Otto Boisselle & Sklar, LLP
20110002895 - Composition for autotransplantation or allotransplantation using dental pulp stem cell, and use of the composition: The object is to provide a novel use application of a dental pulp stem cell collected from a deciduous tooth or a permanent tooth. Disclosed is a composition for autotransplantation or allotransplantation, which is characterized by comprising a dental pulp stem cell collected from a deciduous tooth or a permanent... Agent: Edwards Angell Palmer & Dodge LLP
20110002894 - Compositions and methods for treating and preventing heart tissue degeneration and uses thereof: The present invention provides compositions useful for cardiac therapy comprising a cyclin-associated agent. The present invention also provides kits for use in delivering a cyclin-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. The present invention additionally provides a methods for... Agent: Snr Denton US LLP
20110002893 - Diagnosis and treatment of congenital heart defects using nell1: The present invention provides diagnostic methods for detecting congenital heart defects, or increased risk thereof, based on the Nell1 gene, RNA and protein. The methods include obtaining a biological sample and assessing the presence of a mutation in the Nell1 gene, RNA or protein. The presence of a mutation in... Agent: Ut-battelle, LLC Office Of Intellectual Property
20110002897 - Directed differentiation of stem cells: Disclosed are compositions and methods for producing neural cells from stem cells and uses thereof.... Agent: Patent Correspondence Arnall Golden Gregory LLP
20110002899 - Lymph nodes as a site for regeneration: Methods of transplanting cells, such as hepatocytes, are presented herein. Such methods are useful for treating liver disease as well as other disorders.... Agent: Hirshman Law, LLC
20110002896 - Methods and related compositions for reduction of fat: Compositions and methods useful in the reduction of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating... Agent: K&l Gates LLP
20110002892 - Modular aptamar-regulated ribozymes: An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, comprised of an aptamer sequence, and an actuator domain, comprised of a hammerhead ribozyme sequence. A variety of... Agent: Knobbe Martens Olson & Bear LLP
20110002898 - Vaccine compositions: The invention relates to tumour therapy. In particular, the present invention relates to vaccine compositions comprising allogenic cells modified with hypercytokines for the treatment of cancer in general and for the treatment of melanoma in particular.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20110002903 - Immunogenic control of tumours and tumour cells: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C—(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumour or in the treatment or prevention of a tumour relapse, and in the manufacture of medicaments... Agent: Nixon & Vanderhye, PC
20110002904 - Synovial villi for use with tissue engineering: Synovial villi derived explants and related surgical tools used to repair or prevent damage to injured or diseased tissue, including connective tissue. The tools including a harvesting tool for selectively harvesting synovial villi from the joint of patient and a delivery tool having a bulbous end for delivering the synovial... Agent: Biotech Beach Law Group , PC
20110002905 - Compositions of fat-soluble active ingredients containing protein-polysaccharide conjugates: The present invention relates to compositions containing one or more proteins, one or more polysaccharides and one or more fat-soluble active ingredients and their use for the enrichment, fortification and/or coloration of food beverages, animal feed and/or cosmetics.... Agent: Nixon & Vanderhye, PC
20110002906 - Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes: The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable... Agent: Ballard Spahr LLP
20110002907 - Methods, systems, compositions and dosage forms for diagnosing and treating male infertility: Methods and systems are provided for diagnosing male infertility relating to inadequate production of phosphatidic acid and are complementary to the routine tests, assessing sperm count, motility, viability, head morphology, and white blood cell count. Additional therapeutic methods, compositions and dosage forms are provided for treating male infertility that is... Agent: The Law Office Of Michael E. Kondoudis
20110002908 - Treatment of a-galactosidase a deficiency: The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included.... Agent: Lando & Anastasi, LLP
20110002909 - Method, composition, and article of manufacture for providing alpha-1 antitrypsin: The present invention provides a method for providing alpha-1 antitrypsin (α1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with α1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of α1-AT to the subject.... Agent: Womble Carlyle Sandridge & Rice, PLLC
20110002910 - Therapeutic agents comprising pro-apoptotic proteins: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.... Agent: Fulbright & Jaworski, L.L.P.
20110002911 - Method for fermenting natural materials with salt and fermented extracts prepared therefrom: The present invention relates to a method for fermenting natural products with salt and fermented extracts prepared thereby. The method comprises: adding a predetermined amount of salt to at least one of natural products, including medicinal herbs and cereals; naturally fermenting the salted material; and extracting the fermented salted material... Agent: Nixon & Vanderhye, PC
20110002912 - Composition: The present invention relates to a composition for improving stem cell integration. The present invention also relates to a method of improving stem cell integration and kits for improving stem cell integration.... Agent: Banner & Witcoff, Ltd.
20110002914 - Hybrid tetnus toxoid proteins that migrate retrogradely and transynaptically into the cns: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the LacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110002915 - Random and non-random alkylene oxide polymer alloy compositions: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block... Agent: Nixon & Vanderhye, PC
20110002913 - Use of interleukin-4 antagonists and compositions thereof: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that... Agent: Immunex Corporation Law Department
20110002919 - Antagonists of neuropilin receptor function and use thereof: The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.... Agent: David S. Resnick
20110002917 - Antibody constant domain regions and uses thereof: The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically... Agent: Hoxie & Associates LLC
20110002922 - Cell growth inhibitors containing anti-glypican 3 antibody: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.... Agent: Davidson, Davidson & Kappel, LLC
20110002920 - Combination cancer immunotherapy with co-stimulatory molecules: Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity... Agent: Foley & Lardner LLP
20110002921 - Combination cancer immunotherapy with co-stimulatory molecules: Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity... Agent: Foley & Lardner LLP
20110002923 - Methods of inhibiting tumor growth using ttk antagonists: The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like... Agent: Foley & Lardner LLP
20110002918 - Methods of treating diseased tissue: Treatment protocols for severe psoriasis include administering biologics, stopping all administration of the biologics after the severity of the psoriasis has reduced and has reached an equilibrium, mildness and/or a tolerable state of remission, and administering UV phototherapy. The biologics may include, for example, the biologics found in Amevive®, Enbrel®,... Agent: Knobbe Martens Olson & Bear LLP
20110002916 - Plasmodium falciparum antigens and their vaccine and diagnostic applications: The invention concerns novel Plasmodium falciparum antigens and their vaccine and diagnostic applications. More particularly, the invention concerns immunogenic polynucleotide and polypeptide molecules, compositions comprising them, and methods for diagnosis and vaccination of malaria.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20110002924 - Tweak receptor agonists as anti-angiogenic agents: The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.... Agent: Biogen Idec / Finnegan Henderson, LLP
20110002925 - Use of anti-il-20 antibody for treating rheumatoid arthritis and osteoporosis: Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.... Agent: Occhiuti Rohlicek & Tsao, LLP
20110002927 - Antigen-binding polypeptides against cartilage degeneration: The invention provides an antigen-binding polypeptide which is able to penetrate into the cartilage. The disclosed polypeptide, compositions and methods are suitable for the treatment, prevention and/or delay of progression of cartilage degeneration.... Agent: Marshall, Gerstein & Borun LLP
20110002926 - Hepatitis c virus antibodies: This invention relates to humanized antibodies and fragments thereof which bind to hepatitis C virus E2 protein and methods of their use.... Agent: Morrison & Foerster LLP
20110002928 - Uses of mammalian cytokine; related reagents: Provided are methods of treatment for inflammatory and autoimmune disorders of the metabolic system. Also provided are methods of diagnosis.... Agent: Merck C/o Dnax
20110002930 - Activated t cells: Provided are compositions comprising activated T cells and activated T cells armed with bispecific antibodies directed at cancer antigens which are poor responders to alloantigen, and methods of using the compositions to help engraftment and improve anti-tumor effects.... Agent: C. Rachal Winger Intellectual Property Docketing Department
20110002929 - Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid... Agent: Wolf Greenfield & Sacks, P.C.
20110002931 - Bispecific antibodies that bind to complement proteins: The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1... Agent: Ropes & Gray LLP Iprm - Floor 43
20110002932 - Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express... Agent: Michaud-kinney Group LLP
20110002933 - Dr4 antibodies and uses thereof: Death Receptor 4 (DR4) antibodies are provided. The DR4 antibodies may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the DR4 antibodies are also provided.... Agent: Sidley Austin LLP
20110002934 - Uses of anti-cd40 antibodies: This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been... Agent: Alston & Bird LLP
20110002935 - Antibody purification: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.... Agent: Mccarter & English, LLP / Abbott Laboratories Ltd.
20110002936 - Anti-il-6/il-6r antibodies and methods of use thereof: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20110002937 - Method of making hybrid cells that express useful antibodies: This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20110002938 - Hematopoietic cells expressing the protein krtcap3 and ligands for the protein krtcap3: The present invention relates to ex vivo hematopoietic cells characterized by the expression of the protein KRTCAP3 on the surface of said cells, to methods for isolating said cells and to ligands for KRTCAP3.... Agent: Lucas & Mercanti, LLP
20110002939 - monoclonal antibody and a method thereof: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1(D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.... Agent: Dla Piper LLP (us)
20110002941 - Antibodies that specifically bind hedgehog-derived polypeptides: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional... Agent: Dla Piper LLP (us)
20110002942 - Engineered anti-il-23 antibodies: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.... Agent: Merck C/o Dnax
20110002940 - Pathways involved in arteriogenesis and uses thereof: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in a subject suffering from insufficient arteriogenic capacity. These nucleic acids are among other useful in methods for diagnosing insufficient arteriogenic capacity, treating a subject suffering from insufficient arteriogenic capacity and/or stimulating arteriogenic capacity and/or... Agent: Foley And Lardner LLP Suite 500
20110002943 - Use of enterovirus for diagnostics, treatment and prevention of disease: The invention is based on the finding that enterovirus is present in body samples of patients with celiac disease. The invention opens up the possibility for using enteroviruses in diagnosing, preventing, treating and monitoring the treatment of celiac-related diseases. The invention relates to a method for diagnosing, treating and monitoring... Agent: Ladas & Parry LLP
20110002944 - Compositions and methods to promote neural cell growth: The instant invention provides methods and compositions for promoting neural cell growth by inhibiting myelin associated glycoprotein (MAG)-induced inhibition of axonal regeneration. The invention relates to methods for identifying agents that inhibit MAG-induced inhibition of neural cell growth. Methods for inhibiting myelin associated glycoprotein (MAG)-induced inhibition of neural cell growth... Agent: Edwards Angell Palmer & Dodge LLP
20110002945 - Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins: Subunits of antibodies, such as a light chain or a heavy chain, selectively bind to amyloid fibrils and oligomers.... Agent: Howard Eisenberg, Esq.
20110002946 - Immunostimulatory combinations: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.... Agent: Hunton & Williams LLP Intellectual Property Department
20110002947 - Leptomycin derivatives: Leptomycin derivatives having a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody are disclosed. The therapeutic use of such leptomycin derivative conjugates is also described; such conjugates have therapeutic use because they can deliver cytotoxic leptomycin derivatives to... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC
20110002952 - Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kappab activity and use thereof: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof,... Agent: Louis J. Wille Bristol-myers Squibb Company
20110002948 - Identification of a nucleic acid molecule: This invention relates to the identification of a nucleic acid molecule. In particular, this invention relates to a method of using an oligonucleotide designed to a variable region of a nucleic acid molecule to identify A nucleic acid molecule.... Agent: Townsend And Townsend And Crew, LLP
20110002951 - Modified leukotoxin gene and protein: The present invention provides nucleic acid sequences encoding a modified leukotoxin protein, wherein the modification comprises the removal of nucleic acid sequences encoding amino acids within hydrophobic transmembrane domains of full length leukotoxin protein, preferably from Mannheimia haemolytica. The modified leukotoxin proteins are useful in vaccine compositions effective against Mannheimia... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.
20110002950 - Pig edema disease vaccine: A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.
20110002953 - Use of immidazoquinolinamines as adjuvants in dna vaccination: The present invention relates to the use of a 1H-imidazo[4,5-c]quinolin-4-amine derivative as an adjuvant for use with nucleic acid vaccination.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220
20110002949 - Vaccine for the treatment of alzheimer's disease: The invention provides a method for the treatment of a patient having a more severe form of Alzheimer's disease (AD), where the severe form of AD is characterized by pathogenic deposits of amyloid beta peptide (Aβ), comprising the administration of an immunogenic fragment of Aβ capable of inducing an immune... Agent: Merck
20110002954 - Rhoc-based immunotherapy: The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or... Agent: Merchant & Gould PC
20110002955 - Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same: Disclosed is an immunogenic hybrid polypeptide for the prevention and treatment of obesity, in which a mimetic peptide of a B cell epitope of apolipoprotein B-IOO; a rabies virus helper T cell epitope or hepatitis B virus surface antigen helper T cell epitope and a C-terminal peptide fragment of mouse... Agent: Lerner, David, Littenberg, Krumholz & Mentlik
20110002956 - Mutant human cd80 and compositions for and methods of making and using the same: Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.... Agent: Pepper Hamilton LLP
20110002957 - Hapten-carrier conjugates for treating and preventing nicotine addiction: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates... Agent: Foley And Lardner LLP Suite 500
20110002958 - Alphavirus vectors for respiratory pathogen vaccines: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, and alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens,... Agent: Novartis Vaccines And Diagnostics Inc.
20110002959 - Vaccine production for pathogenic bird viral diseases: The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for vaccine production from wild and domestic birds, and preferably waterfowl, that have increased resistant to the viral pathogen. The invention... Agent: Womble Carlyle Sandridge & Rice, PLLC
20110002960 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Grant Anderson LLP
20110002961 - Interleukin 12 paracrine gene delivery enhanced ctl immunotherapy: A method of treating a patient with a disease wherein the patient contains diseased cells which cells contain antigens for identification and which cells are capable of presenting at least part of said antigen on their surface by an HLA class I (or equivalent) molecule, the method comprising administering to... Agent: Fuess & Davidenas
20110002962 - Immunogenic pcpa polypeptides and uses thereof: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PcpA and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the... Agent: Fish & Richardson P.C. (at)
20110002963 - Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC
20110002964 - Methods for cancer treatment using stem cells: Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells. In one embodiment the method comprises removing cancer cells from a patient and culturing the cancer cells in the presence of stem cells under conditions such that the stem cells... Agent: Ekstrom Law Group Suite 120-248
20110002965 - Immunomodulating compounds and related compositions and methods: Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile.... Agent: Steinfl & Bruno
20110002967 - Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same: Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that... Agent: Bozicevic, Field & Francis LLP
20110002966 - Vaginal suppository system and method: A vaginal suppository system contains a formulation comprising active and inactive ingredients, which active ingredients may be nutraceuticals, herbs, vitamins, minerals and other bioactive agents. In an embodiment, the active ingredients comprise Oak gall, true unicorn root, bitter orange peel, tropical almond, heartsease, and zinc oxide. The formulation may be... Agent: Jay M. Schloff
20110002969 - Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors: Peptides of general formula (I): R1AA1-AA2-AA3-AA4-R2 stereoisomers thereof, mixtures thereof or the cosmetically or pharmaceutically acceptable salts thereof, a method for obtaining them, cosmetic or pharmaceutical compositions containing them, and their use for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, mucosae and/or scalp resulting... Agent: Brooks Kushman P.C.
20110002970 - Process for the preparation of nano zinc oxide particles: A process for the preparation of nano zinc oxide particles comprising dissolving a zinc metal precursor in a solvent to obtain a first solution; dissolving a base in an alcohol to obtain an alkali solution; and adding the alkali solution to the first solution over a predetermined period of time... Agent: Fish & Richardson P.C. (at)
20110002971 - Ceria for use as an antimicrobial barrier and disinfectant in a wound dressing: The present invention relates to protecting a human from an infection using a disinfecting agent as described herein and a method for use thereof, more particularly to a rare earth-containing device for protecting a wound and a method for use thereof.... Agent: Sheridan Ross PC
20110002972 - Neuroendocrine factors for treatment of degenerative diseases: The present invention is related to the use of a repellent factor and/or polypeptide for manufacturing of a pharmaceutical composition for treating a disease such as a degenerative disease in particular to the use of a SLIT3 or NETRIN1 protein therefore. The invention is further related to a polypeptide fragment... Agent: Arent Fox LLP
20110002973 - Materials and methods for minimally-invasive administration of a cell-containing flowable composition: The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery... Agent: K&l Gates LLP
20110002974 - Random and non-random alkylene oxide polymer alloy compositions: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block... Agent: Nixon & Vanderhye, PC
20110002975 - Preoperative treatment of post operative pain: A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent... Agent: Mcdermott Will & Emery LLP
20110002976 - Medicated patch: Provided is a medicated patch containing a medicinal agent, an adhesive base material and a tackifier, where the medicinal agent is varenicline or a pharmaceutically acceptable salt thereof, the adhesive base material is a rubbery adhesive base material and the tackifier is a rosin-based tackifier selected from the group consisting... Agent: The Nath Law Group
20110002983 - Compound: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a... Agent: Notaro, Michalos & Zaccaria P.C.
20110002978 - Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof: Conjugates for use in an enzyme prodrug cancer therapy treatment are provided.... Agent: Dunlap Codding, P.C.
20110002982 - Lipid carrier compositions with enhanced blood stability: Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.... Agent: Morrison & Foerster LLP
20110002977 - Liposomal pharmaceutical preparation and method for manufacturing the same: The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a... Agent: Cantor Colburn LLP
20110002981 - Mcpip protection against cardiac dysfunction: Disclosed herein are methods and compositions of treating a patient at risk of experiencing sepsis induced cardiac dysfunction. In exemplary examples, the method involves elevating MCPIP levels in a patient in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable... Agent: Timothy H. Van Dyke
20110002979 - Styrene maleic anhydride based formulation for male contraception and prostate cancer: The invention provides a styrene maleic anhydride based synergistic formulation comprising styrene maleic anhydride [SMA] having lower molecular weight and styrene maleic anhydride [SMA] having higher molecular weight dissolved in DMSO, and being capable of preventing the prostate cancer as well as causing male contraception even when administered in smaller... Agent: Ladas & Parry LLP
20110002980 - Vaccines using nucleic acid-lipid complexes: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated... Agent: Sughrue Mion, PLLC
20110002984 - Formulations comprising exine shells: A formulation containing an active substance encapsulated within an exine shell of a naturally occurring spore, together with a protective additive which is also encapsulated within the exine shell.... Agent: Weaver Austin Villeneuve & Sampson LLP
20110002985 - Abuse resistant drugs, method of use and method of making: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and... Agent: Arent Fox LLP
20110002986 - Stable shellac enteric coating formulation for nutraceutical and pharmaceutical dosage forms: The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying... Agent: Hercules Incorporated Hercules Plaza
20110002987 - Nicorandil carriers with enhanced stability: The invention provides a carrier for nicorandil, which is preferably in form of a blister pack, comprising one or several dose blister pockets each containing at least one tablet of nicorandil, and at least one blister pocket containing a molecular sieve.... Agent: Ohlandt, Greeley, Ruggiero & Perle, L.L.P.
20110002988 - Orally rapidly disintegrating tablet comprising imidafenacin: e
20110002989 - Methods, dosage forms and kits for administering ziprasidone without food: The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method... Agent: Pfizer Inc. Patent Department
20110002990 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods... Agent: Mcandrews Held & Malloy, Ltd
20110002992 - N-sulphonylated amino acid derivatives, method for the production and use thereof: The present invention relates to N-sulfonylated amino acid derivatives, where an aryl radical is linked via the sulfonyl group N-terminally to the amino acid and a radical which comprises at least one imino group and at least one further basic group which represents an optionally modified amino, amidino or guanidino... Agent: Clark & Elbing LLP
20110002991 - Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof: The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods... Agent: Mcandrews Held & Malloy, Ltd
20110002993 - Film coated tablets containing drospirenone as active agent and a method for the preparation thereof: The invention relates to drospirenone containing film-coated tablet with improved resistance against the environmental influences, especially against atmospheric humidity. The invention further relates to a method for the preparation film-coated tablet cores whereby applying the active agent to the core may be accomplished with increased safety.... Agent: Fish & Richardson P.C. (tc)
20110002996 - Acellular tissue matrices made from alpha-1,3-galactose-deficient tissue: The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.... Agent: Finnegan/kci
20110002994 - Method of regulating the th17 pathway and its associated metabolic impact: It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to modulate the biological activity of Th17 cells, and its associated metabolic pathway, for a preventative or a therapeutic purpose... Agent: Cantor Colburn LLP
20110002995 - Pharmaceutical composition for the treatment and prevention of cardiac disease: Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination... Agent: Ladas & Parry
20110002997 - Photoinitiated tissue filler: Visible light-activated polymer cosmetic filler preparations useful in a variety of applications are provided. In some embodiments, the photo-activated polymer composition comprises a conventional polymeric material, such as HA, together with a modified, cross-linkable polymer, such as PEG or PEODA, to permit the formation of crosslinks within the polymer matrix... Agent: Edwards Angell Palmer & Dodge LLP
20110002998 - Process for the production of insecticide-modified bead material composed of expandable polystyrene and insecticide-modified moldings obtainable therefrom: A process for the production of insecticide-modified bead material composed of expandable polystyrene (EPS) by extrusion, encompassing the steps of a) mixing, in a mixer, to incorporate a blowing agent and at least one insecticide from the group of the phenylpyrazoles, chlorfenapyr and hydramethylnon into a polymer melt which comprises... Agent: Connolly Bove Lodge & Hutz, LLP
20110002999 - Biopolymer system for tissue sealing: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and... Agent: Goodwin Procter LLP Patent Administrator
20110003001 - Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound... Agent: Seed Intellectual Property Law Group PLLC
20110003000 - Transvaginal delivery of drugs: Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for... Agent: Pabst Patent Group LLP
20110003003 - Magnetic cells for localizing delivery and tissue repair: Normal or genetically modified cell(s) having magnetic nanoparticle(s) bound (affixed) to their surfaces and methods of delivery to target tissues, e.g. for treatment of disease and or injury.... Agent: Mayer & Williams PC
20110003002 - Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).... Agent: Novartis Corporate Intellectual Property
20110003004 - Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.... Agent: K&l Gates LLP
20110003005 - Methods of treating pdnv and ponv with extended release ondansetron compositions: Extended release ondansetron compositions of the present invention are useful for treating postoperative nausea and vomiting (PONV) and/or postdischarge nausea and vomiting (PDNV).... Agent: Cooley LLP
20110003006 - Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions... Agent: Cooley LLP
20110003007 - Microparticle and pharmaceutical composition thereof: A microparticle includes an agglomerate of a hydrophilic active substance containing particle, which particle includes an amphiphilic polymer composed of a hydrophobic segment of poly (hydroxy acid) and a hydrophilic segment of polysaccharides or polyethylene glycol, and a hydrophilic active substance. It is characterized by an efficient inclusion of the... Agent: Ip Group Of Dla Piper LLP (us)
20110003008 - Mesenchymal stem cell particles: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise... Agent: David S. Resnick
20110003009 - Process for obtaining a rabbit skin comprising biological active substances: The present invention relates to a process for obtaining a rabbit skin containing biologically active substances. The rabbit skin extract is obtained by the process including vaccinating a rabbit subcutaneously with vaccinia virus, feeding the rabbit, killing the rabbit when the skin is inflamed, skinning the rabbit within 15 minutes... Agent: Greer, Burns & Crain
20110003011 - Fungicidal active compound combinations:
20110003013 - Method of increasing metabolism: The present invention provides a method for increasing metabolism and/or energy expenditure in a subject, e.g., to treat or prevent obesity and/or a related condition and/or to reduce adiposity, the method comprising increasing the level and/or activity of Hypoxia Induced Factor 1α (HIF-1α) in a cell, tissue or organ of... Agent: Townsend And Townsend And Crew, LLP
20110003012 - Treating patients with subarachnoid hemorrhage: A method for attenuating vasoconstriction in a patient with subarachnoid hemorrhage by administering to the patient a therapeutically effective amount of a compound which mediates an increase of bioactive nitric oxide in blood or tissue in the subarachnoid space to cause vasodilation in cerebral, carotid and basilar arteries after the... Agent: Bacon & Thomas, PLLC
20110003014 - Low toxicity composition for promoting plant growth: A composition for promoting plant growth includes sulfur, soybean oil, and an emulsifier of a fatty acid and a saponifying aqueous base together forming an emulsion, or a soap or a detergent acting as an emulsifier. Regardless of the form of the emulsifier, a composition as applied to vegetation which... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c
20110003015 - Stabilized composition comprising at least one adrenergic compound: A stabilised composition comprising at least one adrenergic compound and at least one antioxidant selected from the group consisting of a bisulfate, a metabisulfite and a sulfite compound.... Agent: Fish & Richardson P.C. (ny)
20110003016 - Hair care composition: A hair treatment composition comprising a trichogenic material and an anti-dandruff agent.... Agent: Unilever Patent Group
20110003018 - Composition for preventing and treating arthritic diseases: In some embodiments, a composition for the treatment and inhibition or prevention of arthritic diseases includes an extract of mixed herbs, the mixed herbs including an active ingredient with Lonicera japonica THUNB and Anemarrhena asphodeloides BUNGE.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.
20110003017 - Method for preparation of extract from angelica gigas nakai and composition containing the extract: Disclosed is Angelica gigas Nakai extract powder prepared by a process including: (a) preparing 85-100% (v/v) pure ethanol and adjusting a pH value of the ethanol to pH 7-9 with an alkaline solution; (b) adding 3-10× of the prepared ethanol to the total weight of Angelica gigas Nakai herb, which... Agent: Andrus, Sceales, Starke & Sawall, LLP
20110003019 - Extract from palm leaves and a method for producing the same: A method for preparing an herbal extract comprises the steps of pre-treating foliages derive from a plant of Arecaceae family; extracting the pre-treated foliages by using a polar solvent; removing the pre-treated foliages from the used polar solvent; and concentrating the used polar solvent to acquire the herbal extract.... Agent: Dicke, Billig & Czaja
20110003020 - Topical compositions for anti-aging and methods of using same: A pharmaceutical composition for treatment of skin aging including a pharmaceutically effective amount of estriol; a pharmaceutically effective amount of estradiol; a pharmaceutically effective amount of hyaluronic acid; a pharmaceutically effective amount of green tea extract; and a pharmaceutically acceptable carrier is provided. In some embodiments, the composition further includes... Agent: Knobbe Martens Olson & Bear LLP
20110003021 - Composition and method for reducing food intake: The present invention features a composition and method for reducing food intake. The composition of the invention is composed of yerbe maté extract, guarana extract, and damiana extract in combination with a dietary fiber.... Agent: Jane Massey Licata Licata & Tyrrell P.C.
20110003022 - Composition and method: A process of obtaining a saponin-rich component from a plant of the Araliaceae family, the process comprising the steps of: (a) treating a portion of the plant with an extraction solvent in which saponin-containing compounds are soluble; and (b) treating the portion of plant or the extract obtained therefrom to... Agent: Hoffman Warnick LLCPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20130509:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 8.72588 seconds